☰

Juih-Wei Hsu, Master - Publications

Affiliations: 
Neuroscience NYMU 
Tree Info Grants Similar researchers PubMed Report error

1/500 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Ho SY, Chiu CH, Huang YC, Chen CJ, Lien R, Chu SM, Huang CG, Tsao KC, Shih SR, Hsu JF. Investigation and successful control of an echovirus 11 outbreak in neonatal intensive care units. Pediatrics and Neonatology. PMID 31669107 DOI: 10.1016/j.pedneo.2019.09.012  0.312
Low-probability matches (unlikely to be authored by this person)
2013 Tageja N, Korde N, Yuan C, Cole K, Hsu J, Phang S, Avila DN, Taylor T, Mulquin M, Zuchlinski D, Khuu H, Stetler-Stevenson M, Leitman SF, Landgren O, Sportes C. Carfilzomib and Bortezomib Containing Regimens Yield High Rates Of MRD Negative Autologous Hematopoietic Progenitor Cell (HPC) Grafts In Multiple Myeloma (MM) and High Risk Smoldering Myeloma (SMM) Blood. 122: 2030-2030. DOI: 10.1182/blood.v122.21.2030.2030  0.145
2013 Tageja N, Korde N, Yuan C, Cole K, Hsu J, Phang S, Avila DN, Taylor T, Mulquin M, Zuchlinski D, Khuu H, Stetler-Stevenson M, Leitman SF, Landgren O, Sportes C. Carfilzomib and Bortezomib Containing Regimens Yield High Rates Of MRD Negative Autologous Hematopoietic Progenitor Cell (HPC) Grafts In Multiple Myeloma (MM) and High Risk Smoldering Myeloma (SMM) Blood. 122: 2030-2030. DOI: 10.1182/blood.v122.21.2030.2030  0.145
2013 Tageja N, Korde N, Yuan C, Cole K, Hsu J, Phang S, Avila DN, Taylor T, Mulquin M, Zuchlinski D, Khuu H, Stetler-Stevenson M, Leitman SF, Landgren O, Sportes C. Carfilzomib and Bortezomib Containing Regimens Yield High Rates Of MRD Negative Autologous Hematopoietic Progenitor Cell (HPC) Grafts In Multiple Myeloma (MM) and High Risk Smoldering Myeloma (SMM) Blood. 122: 2030-2030. DOI: 10.1182/blood.v122.21.2030.2030  0.145
2013 Tageja N, Korde N, Yuan C, Cole K, Hsu J, Phang S, Avila DN, Taylor T, Mulquin M, Zuchlinski D, Khuu H, Stetler-Stevenson M, Leitman SF, Landgren O, Sportes C. Carfilzomib and Bortezomib Containing Regimens Yield High Rates Of MRD Negative Autologous Hematopoietic Progenitor Cell (HPC) Grafts In Multiple Myeloma (MM) and High Risk Smoldering Myeloma (SMM) Blood. 122: 2030-2030. DOI: 10.1182/blood.v122.21.2030.2030  0.145
2013 Tageja N, Korde N, Yuan C, Cole K, Hsu J, Phang S, Avila DN, Taylor T, Mulquin M, Zuchlinski D, Khuu H, Stetler-Stevenson M, Leitman SF, Landgren O, Sportes C. Carfilzomib and Bortezomib Containing Regimens Yield High Rates Of MRD Negative Autologous Hematopoietic Progenitor Cell (HPC) Grafts In Multiple Myeloma (MM) and High Risk Smoldering Myeloma (SMM) Blood. 122: 2030-2030. DOI: 10.1182/blood.v122.21.2030.2030  0.145
2013 Tageja N, Korde N, Yuan C, Cole K, Hsu J, Phang S, Avila DN, Taylor T, Mulquin M, Zuchlinski D, Khuu H, Stetler-Stevenson M, Leitman SF, Landgren O, Sportes C. Carfilzomib and Bortezomib Containing Regimens Yield High Rates Of MRD Negative Autologous Hematopoietic Progenitor Cell (HPC) Grafts In Multiple Myeloma (MM) and High Risk Smoldering Myeloma (SMM) Blood. 122: 2030-2030. DOI: 10.1182/blood.v122.21.2030.2030  0.145
2013 Tageja N, Korde N, Yuan C, Cole K, Hsu J, Phang S, Avila DN, Taylor T, Mulquin M, Zuchlinski D, Khuu H, Stetler-Stevenson M, Leitman SF, Landgren O, Sportes C. Carfilzomib and Bortezomib Containing Regimens Yield High Rates Of MRD Negative Autologous Hematopoietic Progenitor Cell (HPC) Grafts In Multiple Myeloma (MM) and High Risk Smoldering Myeloma (SMM) Blood. 122: 2030-2030. DOI: 10.1182/blood.v122.21.2030.2030  0.145
2013 Tageja N, Korde N, Yuan C, Cole K, Hsu J, Phang S, Avila DN, Taylor T, Mulquin M, Zuchlinski D, Khuu H, Stetler-Stevenson M, Leitman SF, Landgren O, Sportes C. Carfilzomib and Bortezomib Containing Regimens Yield High Rates Of MRD Negative Autologous Hematopoietic Progenitor Cell (HPC) Grafts In Multiple Myeloma (MM) and High Risk Smoldering Myeloma (SMM) Blood. 122: 2030-2030. DOI: 10.1182/blood.v122.21.2030.2030  0.145
2013 Tageja N, Korde N, Yuan C, Cole K, Hsu J, Phang S, Avila DN, Taylor T, Mulquin M, Zuchlinski D, Khuu H, Stetler-Stevenson M, Leitman SF, Landgren O, Sportes C. Carfilzomib and Bortezomib Containing Regimens Yield High Rates Of MRD Negative Autologous Hematopoietic Progenitor Cell (HPC) Grafts In Multiple Myeloma (MM) and High Risk Smoldering Myeloma (SMM) Blood. 122: 2030-2030. DOI: 10.1182/blood.v122.21.2030.2030  0.145
2013 Tageja N, Korde N, Yuan C, Cole K, Hsu J, Phang S, Avila DN, Taylor T, Mulquin M, Zuchlinski D, Khuu H, Stetler-Stevenson M, Leitman SF, Landgren O, Sportes C. Carfilzomib and Bortezomib Containing Regimens Yield High Rates Of MRD Negative Autologous Hematopoietic Progenitor Cell (HPC) Grafts In Multiple Myeloma (MM) and High Risk Smoldering Myeloma (SMM) Blood. 122: 2030-2030. DOI: 10.1182/blood.v122.21.2030.2030  0.145
2013 Tageja N, Korde N, Yuan C, Cole K, Hsu J, Phang S, Avila DN, Taylor T, Mulquin M, Zuchlinski D, Khuu H, Stetler-Stevenson M, Leitman SF, Landgren O, Sportes C. Carfilzomib and Bortezomib Containing Regimens Yield High Rates Of MRD Negative Autologous Hematopoietic Progenitor Cell (HPC) Grafts In Multiple Myeloma (MM) and High Risk Smoldering Myeloma (SMM) Blood. 122: 2030-2030. DOI: 10.1182/blood.v122.21.2030.2030  0.145
2013 Tageja N, Korde N, Yuan C, Cole K, Hsu J, Phang S, Avila DN, Taylor T, Mulquin M, Zuchlinski D, Khuu H, Stetler-Stevenson M, Leitman SF, Landgren O, Sportes C. Carfilzomib and Bortezomib Containing Regimens Yield High Rates Of MRD Negative Autologous Hematopoietic Progenitor Cell (HPC) Grafts In Multiple Myeloma (MM) and High Risk Smoldering Myeloma (SMM) Blood. 122: 2030-2030. DOI: 10.1182/blood.v122.21.2030.2030  0.145
2013 Tageja N, Korde N, Yuan C, Cole K, Hsu J, Phang S, Avila DN, Taylor T, Mulquin M, Zuchlinski D, Khuu H, Stetler-Stevenson M, Leitman SF, Landgren O, Sportes C. Carfilzomib and Bortezomib Containing Regimens Yield High Rates Of MRD Negative Autologous Hematopoietic Progenitor Cell (HPC) Grafts In Multiple Myeloma (MM) and High Risk Smoldering Myeloma (SMM) Blood. 122: 2030-2030. DOI: 10.1182/blood.v122.21.2030.2030  0.145
2013 Tageja N, Korde N, Yuan C, Cole K, Hsu J, Phang S, Avila DN, Taylor T, Mulquin M, Zuchlinski D, Khuu H, Stetler-Stevenson M, Leitman SF, Landgren O, Sportes C. Carfilzomib and Bortezomib Containing Regimens Yield High Rates Of MRD Negative Autologous Hematopoietic Progenitor Cell (HPC) Grafts In Multiple Myeloma (MM) and High Risk Smoldering Myeloma (SMM) Blood. 122: 2030-2030. DOI: 10.1182/blood.v122.21.2030.2030  0.145
2013 Tageja N, Korde N, Yuan C, Cole K, Hsu J, Phang S, Avila DN, Taylor T, Mulquin M, Zuchlinski D, Khuu H, Stetler-Stevenson M, Leitman SF, Landgren O, Sportes C. Carfilzomib and Bortezomib Containing Regimens Yield High Rates Of MRD Negative Autologous Hematopoietic Progenitor Cell (HPC) Grafts In Multiple Myeloma (MM) and High Risk Smoldering Myeloma (SMM) Blood. 122: 2030-2030. DOI: 10.1182/blood.v122.21.2030.2030  0.145
2013 Tageja N, Korde N, Yuan C, Cole K, Hsu J, Phang S, Avila DN, Taylor T, Mulquin M, Zuchlinski D, Khuu H, Stetler-Stevenson M, Leitman SF, Landgren O, Sportes C. Carfilzomib and Bortezomib Containing Regimens Yield High Rates Of MRD Negative Autologous Hematopoietic Progenitor Cell (HPC) Grafts In Multiple Myeloma (MM) and High Risk Smoldering Myeloma (SMM) Blood. 122: 2030-2030. DOI: 10.1182/blood.v122.21.2030.2030  0.145
2013 Tageja N, Korde N, Yuan C, Cole K, Hsu J, Phang S, Avila DN, Taylor T, Mulquin M, Zuchlinski D, Khuu H, Stetler-Stevenson M, Leitman SF, Landgren O, Sportes C. Carfilzomib and Bortezomib Containing Regimens Yield High Rates Of MRD Negative Autologous Hematopoietic Progenitor Cell (HPC) Grafts In Multiple Myeloma (MM) and High Risk Smoldering Myeloma (SMM) Blood. 122: 2030-2030. DOI: 10.1182/blood.v122.21.2030.2030  0.145
2013 Tageja N, Korde N, Yuan C, Cole K, Hsu J, Phang S, Avila DN, Taylor T, Mulquin M, Zuchlinski D, Khuu H, Stetler-Stevenson M, Leitman SF, Landgren O, Sportes C. Carfilzomib and Bortezomib Containing Regimens Yield High Rates Of MRD Negative Autologous Hematopoietic Progenitor Cell (HPC) Grafts In Multiple Myeloma (MM) and High Risk Smoldering Myeloma (SMM) Blood. 122: 2030-2030. DOI: 10.1182/blood.v122.21.2030.2030  0.145
2013 Tageja N, Korde N, Yuan C, Cole K, Hsu J, Phang S, Avila DN, Taylor T, Mulquin M, Zuchlinski D, Khuu H, Stetler-Stevenson M, Leitman SF, Landgren O, Sportes C. Carfilzomib and Bortezomib Containing Regimens Yield High Rates Of MRD Negative Autologous Hematopoietic Progenitor Cell (HPC) Grafts In Multiple Myeloma (MM) and High Risk Smoldering Myeloma (SMM) Blood. 122: 2030-2030. DOI: 10.1182/blood.v122.21.2030.2030  0.145
2013 Tageja N, Korde N, Yuan C, Cole K, Hsu J, Phang S, Avila DN, Taylor T, Mulquin M, Zuchlinski D, Khuu H, Stetler-Stevenson M, Leitman SF, Landgren O, Sportes C. Carfilzomib and Bortezomib Containing Regimens Yield High Rates Of MRD Negative Autologous Hematopoietic Progenitor Cell (HPC) Grafts In Multiple Myeloma (MM) and High Risk Smoldering Myeloma (SMM) Blood. 122: 2030-2030. DOI: 10.1182/blood.v122.21.2030.2030  0.145
2020 Wang HC, Liao CC, Chu SM, Lai MY, Huang HR, Chiang MC, Fu RH, Hsu JF, Tsai MH. Impacts of Multidrug-Resistant Pathogens and Inappropriate Initial Antibiotic Therapy on the Outcomes of Neonates with Ventilator-Associated Pneumonia. Antibiotics (Basel, Switzerland). 9. PMID 33143219 DOI: 10.3390/antibiotics9110760  0.141
2021 Boehmer TK, Kompaniyets L, Lavery AM, Hsu J, Ko JY, Yusuf H, Romano SD, Gundlapalli AV, Oster ME, Harris AM. Association Between COVID-19 and Myocarditis Using Hospital-Based Administrative Data - United States, March 2020-January 2021. Mmwr. Morbidity and Mortality Weekly Report. 70: 1228-1232. PMID 34473684 DOI: 10.15585/mmwr.mm7035e5  0.14
2021 Wang HC, Tsai MH, Chu SM, Liao CC, Lai MY, Huang HR, Chiang MC, Fu RH, Hsu JF. Clinical characteristics and outcomes of neonates with polymicrobial ventilator-associated pneumonia in the intensive care unit. Bmc Infectious Diseases. 21: 965. PMID 34535089 DOI: 10.1186/s12879-021-06673-9  0.14
2009 Sher Y, Tzeng T, Kan S, Hsu J, Xie X, Han Z, Lin W, Li L, Hung M. Cancer targeted gene therapy of BikDD inhibits orthotopic lung cancer growth and improves long-term survival Oncogene. 28: 3286-3295. DOI: 10.1038/Onc.2009.187  0.138
2019 Miljkovic MD, Conlon KC, Hsu J, Sun C, Wiestner A, Waldmann TA. Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia Blood. 134: 3052-3052. DOI: 10.1182/Blood-2019-130807  0.137
2019 Miljkovic MD, Conlon KC, Hsu J, Sun C, Wiestner A, Waldmann TA. Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia Blood. 134: 3052-3052. DOI: 10.1182/blood-2019-130807  0.137
2019 Miljkovic MD, Conlon KC, Hsu J, Sun C, Wiestner A, Waldmann TA. Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia Blood. 134: 3052-3052. DOI: 10.1182/blood-2019-130807  0.137
2019 Miljkovic MD, Conlon KC, Hsu J, Sun C, Wiestner A, Waldmann TA. Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia Blood. 134: 3052-3052. DOI: 10.1182/blood-2019-130807  0.137
2019 Miljkovic MD, Conlon KC, Hsu J, Sun C, Wiestner A, Waldmann TA. Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia Blood. 134: 3052-3052. DOI: 10.1182/blood-2019-130807  0.137
2019 Miljkovic MD, Conlon KC, Hsu J, Sun C, Wiestner A, Waldmann TA. Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia Blood. 134: 3052-3052. DOI: 10.1182/blood-2019-130807  0.137
2019 Miljkovic MD, Conlon KC, Hsu J, Sun C, Wiestner A, Waldmann TA. Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia Blood. 134: 3052-3052. DOI: 10.1182/blood-2019-130807  0.137
2019 Miljkovic MD, Conlon KC, Hsu J, Sun C, Wiestner A, Waldmann TA. Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia Blood. 134: 3052-3052. DOI: 10.1182/blood-2019-130807  0.137
2019 Miljkovic MD, Conlon KC, Hsu J, Sun C, Wiestner A, Waldmann TA. Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia Blood. 134: 3052-3052. DOI: 10.1182/blood-2019-130807  0.137
2019 Miljkovic MD, Conlon KC, Hsu J, Sun C, Wiestner A, Waldmann TA. Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia Blood. 134: 3052-3052. DOI: 10.1182/blood-2019-130807  0.137
2019 Miljkovic MD, Conlon KC, Hsu J, Sun C, Wiestner A, Waldmann TA. Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia Blood. 134: 3052-3052. DOI: 10.1182/blood-2019-130807  0.137
2019 Miljkovic MD, Conlon KC, Hsu J, Sun C, Wiestner A, Waldmann TA. Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia Blood. 134: 3052-3052. DOI: 10.1182/blood-2019-130807  0.137
2019 Miljkovic MD, Conlon KC, Hsu J, Sun C, Wiestner A, Waldmann TA. Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia Blood. 134: 3052-3052. DOI: 10.1182/blood-2019-130807  0.137
2019 Miljkovic MD, Conlon KC, Hsu J, Sun C, Wiestner A, Waldmann TA. Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia Blood. 134: 3052-3052. DOI: 10.1182/blood-2019-130807  0.137
2019 Miljkovic MD, Conlon KC, Hsu J, Sun C, Wiestner A, Waldmann TA. Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia Blood. 134: 3052-3052. DOI: 10.1182/blood-2019-130807  0.137
2019 Miljkovic MD, Conlon KC, Hsu J, Sun C, Wiestner A, Waldmann TA. Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia Blood. 134: 3052-3052. DOI: 10.1182/blood-2019-130807  0.137
2019 Miljkovic MD, Conlon KC, Hsu J, Sun C, Wiestner A, Waldmann TA. Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia Blood. 134: 3052-3052. DOI: 10.1182/blood-2019-130807  0.137
2019 Miljkovic MD, Conlon KC, Hsu J, Sun C, Wiestner A, Waldmann TA. Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia Blood. 134: 3052-3052. DOI: 10.1182/blood-2019-130807  0.137
2019 Miljkovic MD, Conlon KC, Hsu J, Sun C, Wiestner A, Waldmann TA. Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia Blood. 134: 3052-3052. DOI: 10.1182/blood-2019-130807  0.137
2019 Miljkovic MD, Conlon KC, Hsu J, Sun C, Wiestner A, Waldmann TA. Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia Blood. 134: 3052-3052. DOI: 10.1182/blood-2019-130807  0.137
2021 Hsu JF, Yang MC, Chu SM, Yang LY, Chiang MC, Lai MY, Huang HR, Pan YB, Fu RH, Tsai MH. Therapeutic effects and outcomes of rescue high-frequency oscillatory ventilation for premature infants with severe refractory respiratory failure. Scientific Reports. 11: 8471. PMID 33875758 DOI: 10.1038/s41598-021-88231-6  0.136
2019 Miljkovic MD, Conlon KC, Dubois S, Hsu J, Schlom J, Gulley J, Waldmann TA. Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell Malignancies Blood. 134: 1558-1558. DOI: 10.1182/Blood-2019-128945  0.136
2019 Miljkovic MD, Conlon KC, Dubois S, Hsu J, Schlom J, Gulley J, Waldmann TA. Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell Malignancies Blood. 134: 1558-1558. DOI: 10.1182/blood-2019-128945  0.136
2019 Miljkovic MD, Conlon KC, Dubois S, Hsu J, Schlom J, Gulley J, Waldmann TA. Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell Malignancies Blood. 134: 1558-1558. DOI: 10.1182/blood-2019-128945  0.136
2019 Miljkovic MD, Conlon KC, Dubois S, Hsu J, Schlom J, Gulley J, Waldmann TA. Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell Malignancies Blood. 134: 1558-1558. DOI: 10.1182/blood-2019-128945  0.136
2019 Miljkovic MD, Conlon KC, Dubois S, Hsu J, Schlom J, Gulley J, Waldmann TA. Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell Malignancies Blood. 134: 1558-1558. DOI: 10.1182/blood-2019-128945  0.136
2019 Miljkovic MD, Conlon KC, Dubois S, Hsu J, Schlom J, Gulley J, Waldmann TA. Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell Malignancies Blood. 134: 1558-1558. DOI: 10.1182/blood-2019-128945  0.136
2019 Miljkovic MD, Conlon KC, Dubois S, Hsu J, Schlom J, Gulley J, Waldmann TA. Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell Malignancies Blood. 134: 1558-1558. DOI: 10.1182/blood-2019-128945  0.136
2019 Miljkovic MD, Conlon KC, Dubois S, Hsu J, Schlom J, Gulley J, Waldmann TA. Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell Malignancies Blood. 134: 1558-1558. DOI: 10.1182/blood-2019-128945  0.136
2019 Miljkovic MD, Conlon KC, Dubois S, Hsu J, Schlom J, Gulley J, Waldmann TA. Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell Malignancies Blood. 134: 1558-1558. DOI: 10.1182/blood-2019-128945  0.136
2019 Miljkovic MD, Conlon KC, Dubois S, Hsu J, Schlom J, Gulley J, Waldmann TA. Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell Malignancies Blood. 134: 1558-1558. DOI: 10.1182/blood-2019-128945  0.136
2019 Miljkovic MD, Conlon KC, Dubois S, Hsu J, Schlom J, Gulley J, Waldmann TA. Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell Malignancies Blood. 134: 1558-1558. DOI: 10.1182/blood-2019-128945  0.136
2019 Miljkovic MD, Conlon KC, Dubois S, Hsu J, Schlom J, Gulley J, Waldmann TA. Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell Malignancies Blood. 134: 1558-1558. DOI: 10.1182/blood-2019-128945  0.136
2019 Miljkovic MD, Conlon KC, Dubois S, Hsu J, Schlom J, Gulley J, Waldmann TA. Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell Malignancies Blood. 134: 1558-1558. DOI: 10.1182/blood-2019-128945  0.136
2019 Miljkovic MD, Conlon KC, Dubois S, Hsu J, Schlom J, Gulley J, Waldmann TA. Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell Malignancies Blood. 134: 1558-1558. DOI: 10.1182/blood-2019-128945  0.136
2019 Miljkovic MD, Conlon KC, Dubois S, Hsu J, Schlom J, Gulley J, Waldmann TA. Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell Malignancies Blood. 134: 1558-1558. DOI: 10.1182/blood-2019-128945  0.136
2019 Miljkovic MD, Conlon KC, Dubois S, Hsu J, Schlom J, Gulley J, Waldmann TA. Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell Malignancies Blood. 134: 1558-1558. DOI: 10.1182/blood-2019-128945  0.136
2019 Miljkovic MD, Conlon KC, Dubois S, Hsu J, Schlom J, Gulley J, Waldmann TA. Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell Malignancies Blood. 134: 1558-1558. DOI: 10.1182/blood-2019-128945  0.136
2019 Miljkovic MD, Conlon KC, Dubois S, Hsu J, Schlom J, Gulley J, Waldmann TA. Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell Malignancies Blood. 134: 1558-1558. DOI: 10.1182/blood-2019-128945  0.136
2019 Miljkovic MD, Conlon KC, Dubois S, Hsu J, Schlom J, Gulley J, Waldmann TA. Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell Malignancies Blood. 134: 1558-1558. DOI: 10.1182/blood-2019-128945  0.136
2019 Miljkovic MD, Conlon KC, Dubois S, Hsu J, Schlom J, Gulley J, Waldmann TA. Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell Malignancies Blood. 134: 1558-1558. DOI: 10.1182/blood-2019-128945  0.136
2020 Han Y, Wei Y, Yao J, Chu YY, Li CW, Hsu JL, Nie L, Hung MC. Inhibition of CDK2 reduces EZH2 phosphorylation and reactivates ERα expression in high-grade serous ovarian carcinoma. American Journal of Cancer Research. 10: 1194-1206. PMID 32368395  0.136
2017 Du Y, Yamaguchi H, Hsu JL, Hung M. PARP inhibitors as precision medicine for cancer treatment National Science Review. 4: 576-592. DOI: 10.1093/nsr/nwx027  0.134
2017 Du Y, Yamaguchi H, Hsu JL, Hung M. PARP inhibitors as precision medicine for cancer treatment National Science Review. 4: 576-592. DOI: 10.1093/nsr/nwx027  0.134
2017 Du Y, Yamaguchi H, Hsu JL, Hung M. PARP inhibitors as precision medicine for cancer treatment National Science Review. 4: 576-592. DOI: 10.1093/nsr/nwx027  0.134
2017 Du Y, Yamaguchi H, Hsu JL, Hung M. PARP inhibitors as precision medicine for cancer treatment National Science Review. 4: 576-592. DOI: 10.1093/nsr/nwx027  0.134
2017 Du Y, Yamaguchi H, Hsu JL, Hung M. PARP inhibitors as precision medicine for cancer treatment National Science Review. 4: 576-592. DOI: 10.1093/nsr/nwx027  0.134
2017 Du Y, Yamaguchi H, Hsu JL, Hung M. PARP inhibitors as precision medicine for cancer treatment National Science Review. 4: 576-592. DOI: 10.1093/nsr/nwx027  0.134
2017 Du Y, Yamaguchi H, Hsu JL, Hung M. PARP inhibitors as precision medicine for cancer treatment National Science Review. 4: 576-592. DOI: 10.1093/nsr/nwx027  0.134
2017 Du Y, Yamaguchi H, Hsu JL, Hung M. PARP inhibitors as precision medicine for cancer treatment National Science Review. 4: 576-592. DOI: 10.1093/nsr/nwx027  0.134
2017 Du Y, Yamaguchi H, Hsu JL, Hung M. PARP inhibitors as precision medicine for cancer treatment National Science Review. 4: 576-592. DOI: 10.1093/nsr/nwx027  0.134
2017 Du Y, Yamaguchi H, Hsu JL, Hung M. PARP inhibitors as precision medicine for cancer treatment National Science Review. 4: 576-592. DOI: 10.1093/nsr/nwx027  0.134
2017 Du Y, Yamaguchi H, Hsu JL, Hung M. PARP inhibitors as precision medicine for cancer treatment National Science Review. 4: 576-592. DOI: 10.1093/nsr/nwx027  0.134
2017 Du Y, Yamaguchi H, Hsu JL, Hung M. PARP inhibitors as precision medicine for cancer treatment National Science Review. 4: 576-592. DOI: 10.1093/nsr/nwx027  0.134
2017 Du Y, Yamaguchi H, Hsu JL, Hung M. PARP inhibitors as precision medicine for cancer treatment National Science Review. 4: 576-592. DOI: 10.1093/nsr/nwx027  0.134
2017 Du Y, Yamaguchi H, Hsu JL, Hung M. PARP inhibitors as precision medicine for cancer treatment National Science Review. 4: 576-592. DOI: 10.1093/nsr/nwx027  0.134
2017 Du Y, Yamaguchi H, Hsu JL, Hung M. PARP inhibitors as precision medicine for cancer treatment National Science Review. 4: 576-592. DOI: 10.1093/nsr/nwx027  0.134
2017 Du Y, Yamaguchi H, Hsu JL, Hung M. PARP inhibitors as precision medicine for cancer treatment National Science Review. 4: 576-592. DOI: 10.1093/nsr/nwx027  0.134
2017 Du Y, Yamaguchi H, Hsu JL, Hung M. PARP inhibitors as precision medicine for cancer treatment National Science Review. 4: 576-592. DOI: 10.1093/nsr/nwx027  0.134
2017 Du Y, Yamaguchi H, Hsu JL, Hung M. PARP inhibitors as precision medicine for cancer treatment National Science Review. 4: 576-592. DOI: 10.1093/nsr/nwx027  0.134
2017 Du Y, Yamaguchi H, Hsu JL, Hung M. PARP inhibitors as precision medicine for cancer treatment National Science Review. 4: 576-592. DOI: 10.1093/nsr/nwx027  0.134
2017 Du Y, Yamaguchi H, Hsu JL, Hung M. PARP inhibitors as precision medicine for cancer treatment National Science Review. 4: 576-592. DOI: 10.1093/nsr/nwx027  0.134
2018 Kazandjian D, Korde N, Mailankody S, Zhang Y, Hsu J, Hill E, Morrison C, Divakarla S, Kwok ML, Manasanch EE, Bhutani M, Tageja N, Galera P, Dulau-Florea A, Salem D, et al. A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term Deep Remissions and Prolonged Progression-Free Duration Regardless of Age or Cytogenetic Risk after 5 Years of Follow up Blood. 132: 1957-1957. DOI: 10.1182/Blood-2018-99-111712  0.134
2018 Kazandjian D, Korde N, Mailankody S, Zhang Y, Hsu J, Hill E, Morrison C, Divakarla S, Kwok ML, Manasanch EE, Bhutani M, Tageja N, Galera P, Dulau-Florea A, Salem D, et al. A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term Deep Remissions and Prolonged Progression-Free Duration Regardless of Age or Cytogenetic Risk after 5 Years of Follow up Blood. 132: 1957-1957. DOI: 10.1182/blood-2018-99-111712  0.134
2018 Kazandjian D, Korde N, Mailankody S, Zhang Y, Hsu J, Hill E, Morrison C, Divakarla S, Kwok ML, Manasanch EE, Bhutani M, Tageja N, Galera P, Dulau-Florea A, Salem D, et al. A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term Deep Remissions and Prolonged Progression-Free Duration Regardless of Age or Cytogenetic Risk after 5 Years of Follow up Blood. 132: 1957-1957. DOI: 10.1182/blood-2018-99-111712  0.134
2018 Kazandjian D, Korde N, Mailankody S, Zhang Y, Hsu J, Hill E, Morrison C, Divakarla S, Kwok ML, Manasanch EE, Bhutani M, Tageja N, Galera P, Dulau-Florea A, Salem D, et al. A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term Deep Remissions and Prolonged Progression-Free Duration Regardless of Age or Cytogenetic Risk after 5 Years of Follow up Blood. 132: 1957-1957. DOI: 10.1182/blood-2018-99-111712  0.134
2018 Kazandjian D, Korde N, Mailankody S, Zhang Y, Hsu J, Hill E, Morrison C, Divakarla S, Kwok ML, Manasanch EE, Bhutani M, Tageja N, Galera P, Dulau-Florea A, Salem D, et al. A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term Deep Remissions and Prolonged Progression-Free Duration Regardless of Age or Cytogenetic Risk after 5 Years of Follow up Blood. 132: 1957-1957. DOI: 10.1182/blood-2018-99-111712  0.134
2018 Kazandjian D, Korde N, Mailankody S, Zhang Y, Hsu J, Hill E, Morrison C, Divakarla S, Kwok ML, Manasanch EE, Bhutani M, Tageja N, Galera P, Dulau-Florea A, Salem D, et al. A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term Deep Remissions and Prolonged Progression-Free Duration Regardless of Age or Cytogenetic Risk after 5 Years of Follow up Blood. 132: 1957-1957. DOI: 10.1182/blood-2018-99-111712  0.134
2018 Kazandjian D, Korde N, Mailankody S, Zhang Y, Hsu J, Hill E, Morrison C, Divakarla S, Kwok ML, Manasanch EE, Bhutani M, Tageja N, Galera P, Dulau-Florea A, Salem D, et al. A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term Deep Remissions and Prolonged Progression-Free Duration Regardless of Age or Cytogenetic Risk after 5 Years of Follow up Blood. 132: 1957-1957. DOI: 10.1182/blood-2018-99-111712  0.134
2018 Kazandjian D, Korde N, Mailankody S, Zhang Y, Hsu J, Hill E, Morrison C, Divakarla S, Kwok ML, Manasanch EE, Bhutani M, Tageja N, Galera P, Dulau-Florea A, Salem D, et al. A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term Deep Remissions and Prolonged Progression-Free Duration Regardless of Age or Cytogenetic Risk after 5 Years of Follow up Blood. 132: 1957-1957. DOI: 10.1182/blood-2018-99-111712  0.134
2018 Kazandjian D, Korde N, Mailankody S, Zhang Y, Hsu J, Hill E, Morrison C, Divakarla S, Kwok ML, Manasanch EE, Bhutani M, Tageja N, Galera P, Dulau-Florea A, Salem D, et al. A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term Deep Remissions and Prolonged Progression-Free Duration Regardless of Age or Cytogenetic Risk after 5 Years of Follow up Blood. 132: 1957-1957. DOI: 10.1182/blood-2018-99-111712  0.134
2018 Kazandjian D, Korde N, Mailankody S, Zhang Y, Hsu J, Hill E, Morrison C, Divakarla S, Kwok ML, Manasanch EE, Bhutani M, Tageja N, Galera P, Dulau-Florea A, Salem D, et al. A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term Deep Remissions and Prolonged Progression-Free Duration Regardless of Age or Cytogenetic Risk after 5 Years of Follow up Blood. 132: 1957-1957. DOI: 10.1182/blood-2018-99-111712  0.134
2018 Kazandjian D, Korde N, Mailankody S, Zhang Y, Hsu J, Hill E, Morrison C, Divakarla S, Kwok ML, Manasanch EE, Bhutani M, Tageja N, Galera P, Dulau-Florea A, Salem D, et al. A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term Deep Remissions and Prolonged Progression-Free Duration Regardless of Age or Cytogenetic Risk after 5 Years of Follow up Blood. 132: 1957-1957. DOI: 10.1182/blood-2018-99-111712  0.134
2018 Kazandjian D, Korde N, Mailankody S, Zhang Y, Hsu J, Hill E, Morrison C, Divakarla S, Kwok ML, Manasanch EE, Bhutani M, Tageja N, Galera P, Dulau-Florea A, Salem D, et al. A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term Deep Remissions and Prolonged Progression-Free Duration Regardless of Age or Cytogenetic Risk after 5 Years of Follow up Blood. 132: 1957-1957. DOI: 10.1182/blood-2018-99-111712  0.134
2018 Kazandjian D, Korde N, Mailankody S, Zhang Y, Hsu J, Hill E, Morrison C, Divakarla S, Kwok ML, Manasanch EE, Bhutani M, Tageja N, Galera P, Dulau-Florea A, Salem D, et al. A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term Deep Remissions and Prolonged Progression-Free Duration Regardless of Age or Cytogenetic Risk after 5 Years of Follow up Blood. 132: 1957-1957. DOI: 10.1182/blood-2018-99-111712  0.134
2018 Kazandjian D, Korde N, Mailankody S, Zhang Y, Hsu J, Hill E, Morrison C, Divakarla S, Kwok ML, Manasanch EE, Bhutani M, Tageja N, Galera P, Dulau-Florea A, Salem D, et al. A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term Deep Remissions and Prolonged Progression-Free Duration Regardless of Age or Cytogenetic Risk after 5 Years of Follow up Blood. 132: 1957-1957. DOI: 10.1182/blood-2018-99-111712  0.134
2018 Kazandjian D, Korde N, Mailankody S, Zhang Y, Hsu J, Hill E, Morrison C, Divakarla S, Kwok ML, Manasanch EE, Bhutani M, Tageja N, Galera P, Dulau-Florea A, Salem D, et al. A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term Deep Remissions and Prolonged Progression-Free Duration Regardless of Age or Cytogenetic Risk after 5 Years of Follow up Blood. 132: 1957-1957. DOI: 10.1182/blood-2018-99-111712  0.134
2018 Kazandjian D, Korde N, Mailankody S, Zhang Y, Hsu J, Hill E, Morrison C, Divakarla S, Kwok ML, Manasanch EE, Bhutani M, Tageja N, Galera P, Dulau-Florea A, Salem D, et al. A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term Deep Remissions and Prolonged Progression-Free Duration Regardless of Age or Cytogenetic Risk after 5 Years of Follow up Blood. 132: 1957-1957. DOI: 10.1182/blood-2018-99-111712  0.134
2018 Kazandjian D, Korde N, Mailankody S, Zhang Y, Hsu J, Hill E, Morrison C, Divakarla S, Kwok ML, Manasanch EE, Bhutani M, Tageja N, Galera P, Dulau-Florea A, Salem D, et al. A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term Deep Remissions and Prolonged Progression-Free Duration Regardless of Age or Cytogenetic Risk after 5 Years of Follow up Blood. 132: 1957-1957. DOI: 10.1182/blood-2018-99-111712  0.134
2018 Kazandjian D, Korde N, Mailankody S, Zhang Y, Hsu J, Hill E, Morrison C, Divakarla S, Kwok ML, Manasanch EE, Bhutani M, Tageja N, Galera P, Dulau-Florea A, Salem D, et al. A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term Deep Remissions and Prolonged Progression-Free Duration Regardless of Age or Cytogenetic Risk after 5 Years of Follow up Blood. 132: 1957-1957. DOI: 10.1182/blood-2018-99-111712  0.134
2018 Kazandjian D, Korde N, Mailankody S, Zhang Y, Hsu J, Hill E, Morrison C, Divakarla S, Kwok ML, Manasanch EE, Bhutani M, Tageja N, Galera P, Dulau-Florea A, Salem D, et al. A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term Deep Remissions and Prolonged Progression-Free Duration Regardless of Age or Cytogenetic Risk after 5 Years of Follow up Blood. 132: 1957-1957. DOI: 10.1182/blood-2018-99-111712  0.134
2018 Kazandjian D, Korde N, Mailankody S, Zhang Y, Hsu J, Hill E, Morrison C, Divakarla S, Kwok ML, Manasanch EE, Bhutani M, Tageja N, Galera P, Dulau-Florea A, Salem D, et al. A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term Deep Remissions and Prolonged Progression-Free Duration Regardless of Age or Cytogenetic Risk after 5 Years of Follow up Blood. 132: 1957-1957. DOI: 10.1182/blood-2018-99-111712  0.134
2017 Hsu JH, Hubbell-Engler B, Adelmant G, Huang J, Joyce CE, Vazquez F, Weir BA, Montgomery P, Tsherniak A, Giacomelli AO, Perry JA, Trowbridge J, Fujiwara Y, Cowley GS, Xie H, et al. Prmt1-mediated translation regulation is a crucial vulnerability of cancer. Cancer Research. PMID 28655788 DOI: 10.1158/0008-5472.Can-17-0216  0.133
2021 Rios-Diaz AJ, Cunning J, Hsu JY, Elfanagely O, Marks JA, Grenda TR, Reilly PM, Broach RB, Fischer JP. Incidence, Burden on the Health Care System, and Factors Associated With Incisional Hernia After Trauma Laparotomy. Jama Surgery. e213104. PMID 34259810 DOI: 10.1001/jamasurg.2021.3104  0.132
2021 Moura Junior V, Westover MB, Li F, Kimchi E, Kennedy M, Benson NM, Moura LM, Hsu J. Hospital complications among older adults: Better processes could reduce the risk of delirium. Health Services Management Research. 9514848211028707. PMID 34247525 DOI: 10.1177/09514848211028707  0.131
2018 Chen YL, Hu CM, Hsu JT, Chang CC, Huang TY, Chiang PH, Chen WY, Chang YT, Chang MC, Tien YW, Lee EY, Jeng YM, Lee WH. Cellular 5-hydroxylmethylcytosine content determines tumorigenic potential and prognosis of pancreatic ductal adenocarcinoma. American Journal of Cancer Research. 8: 2548-2563. PMID 30662811  0.131
2021 Kaufmann TL, Getz KD, Hsu JY, Bennett AV, Takvorian SU, Kamal AH, DeMichele A. Identification of Patient-Reported Outcome Phenotypes Among Oncology Patients With Palliative Care Needs. Jco Oncology Practice. OP2000849. PMID 33760637 DOI: 10.1200/OP.20.00849  0.13
2009 Xie X, Hsu JL, Choi MG, Xia W, Yamaguchi H, Chen CT, Trinh BQ, Lu Z, Ueno NT, Wolf JK, Bast RC, Hung MC. A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. Molecular Cancer Therapeutics. 8: 2375-82. PMID 19671744 DOI: 10.1158/1535-7163.Mct-09-0056  0.13
2009 Xie X, Hsu JL, Choi MG, Xia W, Yamaguchi H, Chen CT, Trinh BQ, Lu Z, Ueno NT, Wolf JK, Bast RC, Hung MC. A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. Molecular Cancer Therapeutics. 8: 2375-82. PMID 19671744 DOI: 10.1158/1535-7163.Mct-09-0056  0.13
2009 Xie X, Hsu JL, Choi MG, Xia W, Yamaguchi H, Chen CT, Trinh BQ, Lu Z, Ueno NT, Wolf JK, Bast RC, Hung MC. A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. Molecular Cancer Therapeutics. 8: 2375-82. PMID 19671744 DOI: 10.1158/1535-7163.Mct-09-0056  0.13
2009 Xie X, Hsu JL, Choi MG, Xia W, Yamaguchi H, Chen CT, Trinh BQ, Lu Z, Ueno NT, Wolf JK, Bast RC, Hung MC. A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. Molecular Cancer Therapeutics. 8: 2375-82. PMID 19671744 DOI: 10.1158/1535-7163.Mct-09-0056  0.13
2009 Xie X, Hsu JL, Choi MG, Xia W, Yamaguchi H, Chen CT, Trinh BQ, Lu Z, Ueno NT, Wolf JK, Bast RC, Hung MC. A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. Molecular Cancer Therapeutics. 8: 2375-82. PMID 19671744 DOI: 10.1158/1535-7163.Mct-09-0056  0.13
2009 Xie X, Hsu JL, Choi MG, Xia W, Yamaguchi H, Chen CT, Trinh BQ, Lu Z, Ueno NT, Wolf JK, Bast RC, Hung MC. A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. Molecular Cancer Therapeutics. 8: 2375-82. PMID 19671744 DOI: 10.1158/1535-7163.Mct-09-0056  0.13
2009 Xie X, Hsu JL, Choi MG, Xia W, Yamaguchi H, Chen CT, Trinh BQ, Lu Z, Ueno NT, Wolf JK, Bast RC, Hung MC. A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. Molecular Cancer Therapeutics. 8: 2375-82. PMID 19671744 DOI: 10.1158/1535-7163.Mct-09-0056  0.13
2009 Xie X, Hsu JL, Choi MG, Xia W, Yamaguchi H, Chen CT, Trinh BQ, Lu Z, Ueno NT, Wolf JK, Bast RC, Hung MC. A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. Molecular Cancer Therapeutics. 8: 2375-82. PMID 19671744 DOI: 10.1158/1535-7163.Mct-09-0056  0.13
2009 Xie X, Hsu JL, Choi MG, Xia W, Yamaguchi H, Chen CT, Trinh BQ, Lu Z, Ueno NT, Wolf JK, Bast RC, Hung MC. A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. Molecular Cancer Therapeutics. 8: 2375-82. PMID 19671744 DOI: 10.1158/1535-7163.Mct-09-0056  0.13
2009 Xie X, Hsu JL, Choi MG, Xia W, Yamaguchi H, Chen CT, Trinh BQ, Lu Z, Ueno NT, Wolf JK, Bast RC, Hung MC. A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. Molecular Cancer Therapeutics. 8: 2375-82. PMID 19671744 DOI: 10.1158/1535-7163.Mct-09-0056  0.13
2009 Xie X, Hsu JL, Choi MG, Xia W, Yamaguchi H, Chen CT, Trinh BQ, Lu Z, Ueno NT, Wolf JK, Bast RC, Hung MC. A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. Molecular Cancer Therapeutics. 8: 2375-82. PMID 19671744 DOI: 10.1158/1535-7163.Mct-09-0056  0.13
2009 Xie X, Hsu JL, Choi MG, Xia W, Yamaguchi H, Chen CT, Trinh BQ, Lu Z, Ueno NT, Wolf JK, Bast RC, Hung MC. A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. Molecular Cancer Therapeutics. 8: 2375-82. PMID 19671744 DOI: 10.1158/1535-7163.Mct-09-0056  0.13
2009 Xie X, Hsu JL, Choi MG, Xia W, Yamaguchi H, Chen CT, Trinh BQ, Lu Z, Ueno NT, Wolf JK, Bast RC, Hung MC. A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. Molecular Cancer Therapeutics. 8: 2375-82. PMID 19671744 DOI: 10.1158/1535-7163.Mct-09-0056  0.13
2009 Xie X, Hsu JL, Choi MG, Xia W, Yamaguchi H, Chen CT, Trinh BQ, Lu Z, Ueno NT, Wolf JK, Bast RC, Hung MC. A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. Molecular Cancer Therapeutics. 8: 2375-82. PMID 19671744 DOI: 10.1158/1535-7163.Mct-09-0056  0.13
2009 Xie X, Hsu JL, Choi MG, Xia W, Yamaguchi H, Chen CT, Trinh BQ, Lu Z, Ueno NT, Wolf JK, Bast RC, Hung MC. A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. Molecular Cancer Therapeutics. 8: 2375-82. PMID 19671744 DOI: 10.1158/1535-7163.Mct-09-0056  0.13
2009 Xie X, Hsu JL, Choi MG, Xia W, Yamaguchi H, Chen CT, Trinh BQ, Lu Z, Ueno NT, Wolf JK, Bast RC, Hung MC. A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. Molecular Cancer Therapeutics. 8: 2375-82. PMID 19671744 DOI: 10.1158/1535-7163.Mct-09-0056  0.13
2009 Xie X, Hsu JL, Choi MG, Xia W, Yamaguchi H, Chen CT, Trinh BQ, Lu Z, Ueno NT, Wolf JK, Bast RC, Hung MC. A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. Molecular Cancer Therapeutics. 8: 2375-82. PMID 19671744 DOI: 10.1158/1535-7163.Mct-09-0056  0.13
2009 Xie X, Hsu JL, Choi MG, Xia W, Yamaguchi H, Chen CT, Trinh BQ, Lu Z, Ueno NT, Wolf JK, Bast RC, Hung MC. A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. Molecular Cancer Therapeutics. 8: 2375-82. PMID 19671744 DOI: 10.1158/1535-7163.Mct-09-0056  0.13
2009 Xie X, Hsu JL, Choi MG, Xia W, Yamaguchi H, Chen CT, Trinh BQ, Lu Z, Ueno NT, Wolf JK, Bast RC, Hung MC. A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. Molecular Cancer Therapeutics. 8: 2375-82. PMID 19671744 DOI: 10.1158/1535-7163.Mct-09-0056  0.13
2020 Zhou H, Blevins MA, Hsu JY, Kong D, Galbraith MD, Goodspeed A, Culp-Hill R, Oliphant MU, Ramirez D, Zhang L, Pineiro JT, Mathews Griner L, King R, Barnaeva E, Hu X, et al. A SIX1/EYA2 small molecule inhibitor disrupts EMT and metastasis. Cancer Research. PMID 32341035 DOI: 10.1158/0008-5472.Can-20-0435  0.128
2016 Du Y, Yamaguchi H, Wei Y, Hsu JL, Wang HL, Hsu YH, Lin WC, Yu WH, Leonard PG, Lee GR, Chen MK, Nakai K, Hsu MC, Chen CT, Sun Y, et al. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. Nature Medicine. PMID 26779812 DOI: 10.1038/Nm.4032  0.128
2016 Du Y, Yamaguchi H, Wei Y, Hsu JL, Wang HL, Hsu YH, Lin WC, Yu WH, Leonard PG, Lee GR, Chen MK, Nakai K, Hsu MC, Chen CT, Sun Y, et al. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. Nature Medicine. PMID 26779812 DOI: 10.1038/Nm.4032  0.128
2016 Du Y, Yamaguchi H, Wei Y, Hsu JL, Wang HL, Hsu YH, Lin WC, Yu WH, Leonard PG, Lee GR, Chen MK, Nakai K, Hsu MC, Chen CT, Sun Y, et al. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. Nature Medicine. PMID 26779812 DOI: 10.1038/Nm.4032  0.128
2019 Liu CC, Chou KT, Hsu JW, Lin JH, Hsu TW, Yen DH, Hung SC, Hsu HS. High metabolic rate and stem cell characteristics of esophageal cancer stem-like cells depend on the Hsp27-AKT-HK2 pathway. International Journal of Cancer. PMID 30920655 DOI: 10.1002/ijc.32301  0.127
2019 DeFilipp Z, Ancheta R, Liu Y, Hu ZH, Gale RP, Snyder D, Schouten HC, Kalaycio M, Hildebrandt GC, Ustun C, Daly A, Ganguly S, Inamoto Y, Litzow M, Szer J, ... ... Hsu JW, et al. Maintenance tyrosine kinase inhibitors following allo-HCT for chronic myeloid leukemia: A CIBMTR Study. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 31669399 DOI: 10.1016/j.bbmt.2019.10.017  0.124
2014 Lin CY, Chen HJ, Huang CC, Lai LC, Lu TP, Tseng GC, Kuo TT, Kuok QY, Hsu JL, Sung SY, Hung MC, Sher YP. ADAM9 promotes lung cancer metastases to brain by a plasminogen activator-based pathway. Cancer Research. 74: 5229-43. PMID 25060522 DOI: 10.1158/0008-5472.CAN-13-2995  0.123
2014 Lin CY, Chen HJ, Huang CC, Lai LC, Lu TP, Tseng GC, Kuo TT, Kuok QY, Hsu JL, Sung SY, Hung MC, Sher YP. ADAM9 promotes lung cancer metastases to brain by a plasminogen activator-based pathway. Cancer Research. 74: 5229-43. PMID 25060522 DOI: 10.1158/0008-5472.CAN-13-2995  0.123
2014 Lin CY, Chen HJ, Huang CC, Lai LC, Lu TP, Tseng GC, Kuo TT, Kuok QY, Hsu JL, Sung SY, Hung MC, Sher YP. ADAM9 promotes lung cancer metastases to brain by a plasminogen activator-based pathway. Cancer Research. 74: 5229-43. PMID 25060522 DOI: 10.1158/0008-5472.CAN-13-2995  0.123
2014 Lin CY, Chen HJ, Huang CC, Lai LC, Lu TP, Tseng GC, Kuo TT, Kuok QY, Hsu JL, Sung SY, Hung MC, Sher YP. ADAM9 promotes lung cancer metastases to brain by a plasminogen activator-based pathway. Cancer Research. 74: 5229-43. PMID 25060522 DOI: 10.1158/0008-5472.CAN-13-2995  0.123
2014 Lin CY, Chen HJ, Huang CC, Lai LC, Lu TP, Tseng GC, Kuo TT, Kuok QY, Hsu JL, Sung SY, Hung MC, Sher YP. ADAM9 promotes lung cancer metastases to brain by a plasminogen activator-based pathway. Cancer Research. 74: 5229-43. PMID 25060522 DOI: 10.1158/0008-5472.CAN-13-2995  0.123
2014 Lin CY, Chen HJ, Huang CC, Lai LC, Lu TP, Tseng GC, Kuo TT, Kuok QY, Hsu JL, Sung SY, Hung MC, Sher YP. ADAM9 promotes lung cancer metastases to brain by a plasminogen activator-based pathway. Cancer Research. 74: 5229-43. PMID 25060522 DOI: 10.1158/0008-5472.CAN-13-2995  0.123
2014 Lin CY, Chen HJ, Huang CC, Lai LC, Lu TP, Tseng GC, Kuo TT, Kuok QY, Hsu JL, Sung SY, Hung MC, Sher YP. ADAM9 promotes lung cancer metastases to brain by a plasminogen activator-based pathway. Cancer Research. 74: 5229-43. PMID 25060522 DOI: 10.1158/0008-5472.CAN-13-2995  0.123
2021 Hsu JF, Chang YF, Cheng HJ, Yang C, Lin CY, Chu SM, Huang HR, Chiang MC, Wang HC, Tsai MH. Machine Learning Approaches to Predict In-Hospital Mortality among Neonates with Clinically Suspected Sepsis in the Neonatal Intensive Care Unit. Journal of Personalized Medicine. 11. PMID 34442338 DOI: 10.3390/jpm11080695  0.122
2016 Wang HY, Chang YL, Cheng CC, Chao MW, Lin SI, Pan SL, Hsu CC, Liu TW, Cheng HC, Tseng CP, Liu SJ, Tsai HJ, Chang HY, Hsu JT. Glucocorticoids may compromise the effect of gefitinib in non-small cell lung cancer. Oncotarget. PMID 27835586 DOI: 10.18632/oncotarget.13185  0.122
2020 Chaekal OK, Scaradavou A, Masson Frenet E, Albano MS, Cushing M, Desai P, Dobrila L, Gergis U, Guarneri D, Hsu JM, Lee S, Mayer SA, Phillips AA, Orfali N, Ritchie EK, et al. Adoptive immunotherapy with CB following chemotherapy for patients with refractory myeloid malignancy: chimerism and response. Blood Advances. 4: 5146-5156. PMID 33091124 DOI: 10.1182/bloodadvances.2020002805  0.121
2011 Chen CT, Yamaguchi H, Lee HJ, Du Y, Lee HH, Xia W, Yu WH, Hsu JL, Yen CJ, Sun HL, Wang Y, Yeh ET, Hortobagyi GN, Hung MC. Dual targeting of tumor angiogenesis and chemotherapy by endostatin-cytosine deaminase-uracil phosphoribosyltransferase. Molecular Cancer Therapeutics. 10: 1327-36. PMID 21610170 DOI: 10.1158/1535-7163.MCT-10-1117  0.121
2011 Chen CT, Yamaguchi H, Lee HJ, Du Y, Lee HH, Xia W, Yu WH, Hsu JL, Yen CJ, Sun HL, Wang Y, Yeh ET, Hortobagyi GN, Hung MC. Dual targeting of tumor angiogenesis and chemotherapy by endostatin-cytosine deaminase-uracil phosphoribosyltransferase. Molecular Cancer Therapeutics. 10: 1327-36. PMID 21610170 DOI: 10.1158/1535-7163.MCT-10-1117  0.121
2011 Chen CT, Yamaguchi H, Lee HJ, Du Y, Lee HH, Xia W, Yu WH, Hsu JL, Yen CJ, Sun HL, Wang Y, Yeh ET, Hortobagyi GN, Hung MC. Dual targeting of tumor angiogenesis and chemotherapy by endostatin-cytosine deaminase-uracil phosphoribosyltransferase. Molecular Cancer Therapeutics. 10: 1327-36. PMID 21610170 DOI: 10.1158/1535-7163.MCT-10-1117  0.121
2011 Chen CT, Yamaguchi H, Lee HJ, Du Y, Lee HH, Xia W, Yu WH, Hsu JL, Yen CJ, Sun HL, Wang Y, Yeh ET, Hortobagyi GN, Hung MC. Dual targeting of tumor angiogenesis and chemotherapy by endostatin-cytosine deaminase-uracil phosphoribosyltransferase. Molecular Cancer Therapeutics. 10: 1327-36. PMID 21610170 DOI: 10.1158/1535-7163.MCT-10-1117  0.121
2011 Chen CT, Yamaguchi H, Lee HJ, Du Y, Lee HH, Xia W, Yu WH, Hsu JL, Yen CJ, Sun HL, Wang Y, Yeh ET, Hortobagyi GN, Hung MC. Dual targeting of tumor angiogenesis and chemotherapy by endostatin-cytosine deaminase-uracil phosphoribosyltransferase. Molecular Cancer Therapeutics. 10: 1327-36. PMID 21610170 DOI: 10.1158/1535-7163.MCT-10-1117  0.121
2011 Chen CT, Yamaguchi H, Lee HJ, Du Y, Lee HH, Xia W, Yu WH, Hsu JL, Yen CJ, Sun HL, Wang Y, Yeh ET, Hortobagyi GN, Hung MC. Dual targeting of tumor angiogenesis and chemotherapy by endostatin-cytosine deaminase-uracil phosphoribosyltransferase. Molecular Cancer Therapeutics. 10: 1327-36. PMID 21610170 DOI: 10.1158/1535-7163.MCT-10-1117  0.121
2011 Chen CT, Yamaguchi H, Lee HJ, Du Y, Lee HH, Xia W, Yu WH, Hsu JL, Yen CJ, Sun HL, Wang Y, Yeh ET, Hortobagyi GN, Hung MC. Dual targeting of tumor angiogenesis and chemotherapy by endostatin-cytosine deaminase-uracil phosphoribosyltransferase. Molecular Cancer Therapeutics. 10: 1327-36. PMID 21610170 DOI: 10.1158/1535-7163.MCT-10-1117  0.121
2011 Chen CT, Yamaguchi H, Lee HJ, Du Y, Lee HH, Xia W, Yu WH, Hsu JL, Yen CJ, Sun HL, Wang Y, Yeh ET, Hortobagyi GN, Hung MC. Dual targeting of tumor angiogenesis and chemotherapy by endostatin-cytosine deaminase-uracil phosphoribosyltransferase. Molecular Cancer Therapeutics. 10: 1327-36. PMID 21610170 DOI: 10.1158/1535-7163.MCT-10-1117  0.121
2011 Chen CT, Yamaguchi H, Lee HJ, Du Y, Lee HH, Xia W, Yu WH, Hsu JL, Yen CJ, Sun HL, Wang Y, Yeh ET, Hortobagyi GN, Hung MC. Dual targeting of tumor angiogenesis and chemotherapy by endostatin-cytosine deaminase-uracil phosphoribosyltransferase. Molecular Cancer Therapeutics. 10: 1327-36. PMID 21610170 DOI: 10.1158/1535-7163.MCT-10-1117  0.121
2013 Yamaguchi H, Hsu JL, Chen CT, Wang YN, Hsu MC, Chang SS, Du Y, Ko HW, Herbst R, Hung MC. Caspase-independent cell death is involved in the negative effect of EGF receptor inhibitors on cisplatin in non-small cell lung cancer cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 845-54. PMID 23344263 DOI: 10.1158/1078-0432.CCR-12-2621  0.121
2013 Yamaguchi H, Hsu JL, Chen CT, Wang YN, Hsu MC, Chang SS, Du Y, Ko HW, Herbst R, Hung MC. Caspase-independent cell death is involved in the negative effect of EGF receptor inhibitors on cisplatin in non-small cell lung cancer cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 845-54. PMID 23344263 DOI: 10.1158/1078-0432.CCR-12-2621  0.121
2016 Lim SO, Li CW, Xia W, Lee HH, Chang SS, Shen J, Hsu JL, Raftery D, Djukovic D, Gu H, Chang WC, Wang HL, Chen ML, Huo L, Chen CH, et al. EGFR signaling enhances aerobic glycolysis in triple negative breast cancer cells to promote tumor growth and immune escape. Cancer Research. PMID 26759242 DOI: 10.1158/0008-5472.Can-15-2478  0.121
2016 Lim SO, Li CW, Xia W, Lee HH, Chang SS, Shen J, Hsu JL, Raftery D, Djukovic D, Gu H, Chang WC, Wang HL, Chen ML, Huo L, Chen CH, et al. EGFR signaling enhances aerobic glycolysis in triple negative breast cancer cells to promote tumor growth and immune escape. Cancer Research. PMID 26759242 DOI: 10.1158/0008-5472.Can-15-2478  0.121
2019 Hsu JH, Chang PM, Cheng TS, Kuo YL, Wu AT, Tran TH, Yang YH, Chen JM, Tsai YC, Chu YS, Huang TH, Huang CF, Lai JM. Identification of Withaferin A as a Potential Candidate for Anti-Cancer Therapy in Non-Small Cell Lung Cancer. Cancers. 11. PMID 31319622 DOI: 10.3390/cancers11071003  0.12
2018 Barry KC, Hsu J, Broz ML, Cueto FJ, Binnewies M, Combes AJ, Nelson AE, Loo K, Kumar R, Rosenblum MD, Alvarado MD, Wolf DM, Bogunovic D, Bhardwaj N, Daud AI, et al. A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. Nature Medicine. PMID 29942093 DOI: 10.1038/S41591-018-0085-8  0.12
2014 Hsu YH, Yao J, Chan LC, Wu TJ, Hsu JL, Fang YF, Wei Y, Wu Y, Huang WC, Liu CL, Chang YC, Wang MY, Li CW, Shen J, Chen MK, et al. Definition of PKC-α, CDK6, and MET as therapeutic targets in triple-negative breast cancer. Cancer Research. 74: 4822-35. PMID 24970481 DOI: 10.1158/0008-5472.Can-14-0584  0.119
2017 Deutsch E, Moyal EC, Gregorc V, Zucali PA, Menard J, Soria JC, Kloos I, Hsu J, Luan Y, Liu E, Vezan R, Graef T, Rivera S. A phase 1 dose-escalation study of the oral histone deacetylase inhibitor abexinostat in combination with standard hypofractionated radiotherapy in advanced solid tumors. Oncotarget. 8: 56199-56209. PMID 28915584 DOI: 10.18632/Oncotarget.14147  0.119
2017 Kim J, Chhour P, Hsu J, Litt HI, Ferrari VA, Popovtzer R, Cormode DP. Use of Nanoparticle Contrast Agents for Cell Tracking with Computed Tomography. Bioconjugate Chemistry. PMID 28485976 DOI: 10.1021/acs.bioconjchem.7b00194  0.119
2020 Chowdhury S, Sripathy S, Webster A, Park A, Lao U, Hsu JH, Loe T, Bedalov A, Simon JA. Discovery of Selective SIRT2 Inhibitors as Therapeutic Agents in B-Cell Lymphoma and Other Malignancies. Molecules (Basel, Switzerland). 25. PMID 31973227 DOI: 10.3390/Molecules25030455  0.118
2021 Wei Y, Hsu JC, Chen W, Chew EY, Ding Y. Identification and inference for subgroups with differential treatment efficacy from randomized controlled trials with survival outcomes through multiple testing. Statistics in Medicine. PMID 34542190 DOI: 10.1002/sim.9196  0.117
2019 Reynolds K, Mues KE, Harrison TN, Qian L, Chen S, Hsu JY, Philip KJ, Monda KL, Reading SR, Brar SS. Trends in statin utilization among adults with severe peripheral artery disease including critical limb ischemia in an integrated healthcare delivery system. Vascular Medicine (London, England). 1358863X19871100. PMID 31512991 DOI: 10.1177/1358863X19871100  0.116
2017 Dréno B, Ribas A, Larkin J, Ascierto PA, Hauschild A, Thomas L, Grob JJ, Koralek DO, Rooney I, Hsu JJ, McKenna EF, McArthur GA. Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 28444112 DOI: 10.1093/annonc/mdx040  0.116
2019 Hsu J, Chen Z, Shore T, Gergis U, Mayer S, Phillips A, Guarner D, Hsu M, Cushing MM, Van Besien K. OUTCOMES OF ALLOGENEIC STEM CELL TRANSPLANT FOR ELDERLY PATIENTS WITH HEMATOLOGIC MALIGNANCIES. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 31891814 DOI: 10.1016/j.bbmt.2019.12.766  0.115
2019 Gomez-Arteaga A, Mark TM, Guarneri D, Christos PJ, Gergis U, Greenberg JD, Hsu J, Mayer SA, Niesvizky R, Pearse RN, Phillips AA, Rossi A, Coleman M, van Besien K, Shore TB. High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma. Bone Marrow Transplantation. PMID 31190006 DOI: 10.1038/s41409-019-0587-0  0.115
2018 Liu CC, Lin JH, Hsu TW, Hsu JW, Chang JW, Su K, Hsu HS, Hung SC. Collagen XVII/laminin-5 activates epithelial-to-mesenchymal transition and is associated with poor prognosis in lung cancer. Oncotarget. 9: 1656-1672. PMID 29416721 DOI: 10.18632/oncotarget.11208  0.115
2019 Huang WC, Huang CC, Wu PC, Chen CJ, Cheng YH, Chen HC, Lee CH, Wu MF, Hsu JY. The association between airflow limitation and blood eosinophil levels with treatment outcomes in patients with chronic obstructive pulmonary disease and prolonged mechanical ventilation. Scientific Reports. 9: 13420. PMID 31530874 DOI: 10.1038/s41598-019-49918-z  0.115
2021 Pierrie SN, Seymour RB, Wally MK, Studnek J, Infinger A, Hsu JR. Pilot randomized trial of pre-hospital advanced therapies for the control of hemorrhage (PATCH) using pelvic binders. The American Journal of Emergency Medicine. 42: 43-48. PMID 33440330 DOI: 10.1016/j.ajem.2020.12.082  0.114
2017 Yamaguchi H, Du Y, Nakai K, Ding M, Chang SS, Hsu JL, Yao J, Wei Y, Nie L, Jiao S, Chang WC, Chen CH, Yu Y, Hortobagyi GN, Hung MC. EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer. Oncogene. PMID 28925391 DOI: 10.1038/Onc.2017.311  0.114
2018 Reilley MJ, McCoon P, Cook C, Lyne P, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, Curran M, Liu Q, Zhou T, Schmidt J, Jo M, ... ... Hsu J, et al. STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial. Journal For Immunotherapy of Cancer. 6: 119. PMID 30446007 DOI: 10.1186/S40425-018-0436-5  0.114
2012 Yamaguchi H, Hsu JL, Hung MC. Regulation of ubiquitination-mediated protein degradation by survival kinases in cancer. Frontiers in Oncology. 2: 15. PMID 22649777 DOI: 10.3389/fonc.2012.00015  0.112
2012 Yamaguchi H, Hsu JL, Hung MC. Regulation of ubiquitination-mediated protein degradation by survival kinases in cancer. Frontiers in Oncology. 2: 15. PMID 22649777 DOI: 10.3389/fonc.2012.00015  0.112
2017 Moreb JS, Byrne M, Shugarman I, Zou F, Xiong S, May WS, Norkin M, Hiemenz J, Brown R, Cogle C, Wingard JR, Hsu JW. Poor peripheral blood stem cell mobilization affects long-term outcomes in multiple myeloma patients undergoing autologous stem cell transplantation. Journal of Clinical Apheresis. PMID 28556233 DOI: 10.1002/jca.21556  0.112
2016 Srinivas SK, Small DS, Macheras M, Hsu JY, Caldwell D, Lorch S. Evaluating the impact of the laborist model of obstetric care on maternal and neonatal outcomes. American Journal of Obstetrics and Gynecology. PMID 27530491 DOI: 10.1016/j.ajog.2016.08.007  0.111
2017 Pal SK, He M, Chen L, Yang L, Pillai R, Twardowski P, Hsu J, Kortylewski M, Jones JO. Synaptophysin expression on circulating tumor cells in patients with castration resistant prostate cancer undergoing treatment with abiraterone acetate or enzalutamide. Urologic Oncology. PMID 29289429 DOI: 10.1016/J.Urolonc.2017.12.006  0.111
2018 Dizman N, Adashek JJ, Hsu J, Bergerot PG, Bergerot CD, Pal SK. Adjuvant treatment in renal cell carcinoma. Clinical Advances in Hematology & Oncology : H&O. 16: 555-563. PMID 30148828  0.111
2016 Deutsch E, Cohen-Jonathan Moyal E, Gregorc V, Zucali PA, Menard J, Soria JC, Kloos I, Hsu J, Luan Y, Liu E, Vezan R, Graef T, Rivera S. A phase 1 dose-escalation study of the oral histone deacetylase inhibitor abexinostat in combination with standard hypofractionated radiotherapy in advanced solid tumors. Oncotarget. PMID 28030806 DOI: 10.18632/oncotarget.14147  0.111
2017 Tsai MH, Hsu JF, Chu SM, Chang PJ, Lai MY, Wu IH, Huang HR, Chiang MC, Fu RH, Lu JJ. Clinical and microbiological characteristics, and impact of therapeutic strategies on the outcomes of children with candidemia. Scientific Reports. 7: 1083. PMID 28439070 DOI: 10.1038/s41598-017-01123-6  0.11
2021 Hsu JC, Jaminion F, Guerini E, Balas B, Bordogna W, Morcos PN, Frey N. Pharmacometric analyses of alectinib to facilitate approval of the optimal dose for the first-line treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer. Cpt: Pharmacometrics & Systems Pharmacology. PMID 34547184 DOI: 10.1002/psp4.12702  0.11
2016 Li CW, Xia W, Lim SO, Hsu JL, Huo L, Wu Y, Li LY, Lai CC, Chang SS, Hsu YH, Sun HL, Kim J, Yamaguchi H, Lee DF, Wang H, ... Hsu JM, et al. AKT1 inhibits epithelial-to-mesenchymal transition in breast cancer through phosphorylation-dependent Twist1 degradation. Cancer Research. PMID 26759241 DOI: 10.1158/0008-5472.CAN-15-1941  0.109
2017 Hsu JC, Chang SM, Lu CY. Geographic Variations and Time Trends in Cancer Treatments in Taiwan. Bmc Public Health. 18: 89. PMID 28768504 DOI: 10.1186/s12889-017-4615-y  0.109
2016 Kuo HP, Ezell SA, Hsieh S, Schweighofer KJ, Cheung LW, Wu S, Apatira M, Sirisawad M, Eckert K, Liang Y, Hsu J, Chen CT, Beaupre D, Chang BY. The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma. American Journal of Cancer Research. 6: 2489-2501. PMID 27904766 DOI: 10.1182/Blood.V126.23.699.699  0.109
2019 Lee YL, Hsu JF, Yang CJ. Tracheoesophageal Fistula in a Patient with Advanced Non-Small Cell Lung Cancer Who Received Chemoradiotherapy and Ramucirumab. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 14: e17-e18. PMID 30579551 DOI: 10.1016/j.jtho.2018.08.2031  0.109
2018 Gergis U, Frenet EM, Shore T, Mayer S, Phillips A, Hsu JM, Roboz G, Ritchie E, Scandura J, Lee S, Desai P, Samuel M, Ball J, Blanco A, Romeo C, et al. Adoptive Immunotherapy with Cord Blood for the treatment of refractory Acute Myeloid Leukemia: feasibility, safety and preliminary outcomes. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 30414955 DOI: 10.1016/j.bbmt.2018.11.002  0.109
2020 Schmidt S, Liu Y, Hu ZH, Williams KM, Lazarus HM, Vij R, Kharfan-Dabaja MA, Ortí G, Wiernik PH, Weisdorf D, Kamble RT, Herzig R, Wirk B, Cerny J, Bacher U, ... ... Hsu JW, et al. The Role of Donor Lymphocyte Infusion (DLI) in Post Hematopoietic Cell Transplant (HCT) Relapse for Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 32062061 DOI: 10.1016/j.bbmt.2020.02.006  0.108
2012 Li CW, Xia W, Huo L, Lim SO, Wu Y, Hsu JL, Chao CH, Yamaguchi H, Yang NK, Ding Q, Wang Y, Lai YJ, LaBaff AM, Wu TJ, Lin BR, et al. Epithelial-mesenchymal transition induced by TNF-α requires NF-κB-mediated transcriptional upregulation of Twist1 Cancer Research. 72: 1290-1300. PMID 22253230 DOI: 10.1158/0008-5472.CAN-11-3123  0.108
2012 Li CW, Xia W, Huo L, Lim SO, Wu Y, Hsu JL, Chao CH, Yamaguchi H, Yang NK, Ding Q, Wang Y, Lai YJ, LaBaff AM, Wu TJ, Lin BR, et al. Epithelial-mesenchymal transition induced by TNF-α requires NF-κB-mediated transcriptional upregulation of Twist1 Cancer Research. 72: 1290-1300. PMID 22253230 DOI: 10.1158/0008-5472.CAN-11-3123  0.108
2012 Li CW, Xia W, Huo L, Lim SO, Wu Y, Hsu JL, Chao CH, Yamaguchi H, Yang NK, Ding Q, Wang Y, Lai YJ, LaBaff AM, Wu TJ, Lin BR, et al. Epithelial-mesenchymal transition induced by TNF-α requires NF-κB-mediated transcriptional upregulation of Twist1 Cancer Research. 72: 1290-1300. PMID 22253230 DOI: 10.1158/0008-5472.CAN-11-3123  0.108
2012 Li CW, Xia W, Huo L, Lim SO, Wu Y, Hsu JL, Chao CH, Yamaguchi H, Yang NK, Ding Q, Wang Y, Lai YJ, LaBaff AM, Wu TJ, Lin BR, et al. Epithelial-mesenchymal transition induced by TNF-α requires NF-κB-mediated transcriptional upregulation of Twist1 Cancer Research. 72: 1290-1300. PMID 22253230 DOI: 10.1158/0008-5472.CAN-11-3123  0.108
2018 Hsu JL, Bryant CE, Papadimitrious MS, Kong B, Gasiorowski RE, Orellana D, McGuire HM, Groth BFS, Joshua DE, Ho PJ, Larsen S, Iland HJ, Gibson J, Clark GJ, Fromm PD, et al. A blood dendritic cell vaccine for acute myeloid leukemia expands anti-tumor T cell responses at remission. Oncoimmunology. 7: e1419114. PMID 29632738 DOI: 10.1080/2162402X.2017.1419114  0.108
2019 Hsu JS, Zhang R, Yeung F, Tang CSM, Wong JKL, So MT, Xia H, Sham P, Tam PK, Li M, Wong KKY, Garcia-Barcelo MM. Cancer gene mutations in congenital pulmonary airway malformation patients. Erj Open Research. 5. PMID 30740464 DOI: 10.1183/23120541.00196-2018  0.108
2017 Hsu J, Artz A, Mayer SA, Guarner D, Bishop MR, Reich-Slotky R, Smith SM, Greenberg J, Kline J, Ferrante R, Phillips AA, Gergis U, Liu H, Stock W, Cushing M, et al. Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and CLL. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 29128555 DOI: 10.1016/j.bbmt.2017.10.040  0.108
2017 Chang JJ, Lin MS, Chen TH, Chen DY, Chen SW, Hsu JT, Wang PC, Lin YS. Heart Failure and Mortality of Adult Survivors from Acute Myocarditis Requiring Intensive Care Treatment - A Nationwide Cohort Study. International Journal of Medical Sciences. 14: 1241-1250. PMID 29104480 DOI: 10.7150/ijms.20618  0.108
2018 Hsu J, Donnelly JP, Moore JX, Meneses K, Williams G, Wang HE. National characteristics of Emergency Department visits by patients with cancer in the United States. The American Journal of Emergency Medicine. PMID 29573899 DOI: 10.1016/J.Ajem.2018.03.025  0.107
2019 Han Y, Li CW, Hsu JM, Hsu JL, Chan LC, Tan X, He GJ. Metformin reverses PARP inhibitors-induced epithelial-mesenchymal transition and PD-L1 upregulation in triple-negative breast cancer. American Journal of Cancer Research. 9: 800-815. PMID 31106005  0.107
2020 Myong C, Hull P, Price M, Hsu J, Newhouse JP, Fung V. The impact of funding for federally qualified health centers on utilization and emergency department visits in Massachusetts. Plos One. 15: e0243279. PMID 33270778 DOI: 10.1371/journal.pone.0243279  0.107
2020 Wohler AD, Kneisl JS, Macknet DM, Hysong AA, Kaney K, Moroney S, Hsu JR. Surgical Re-entry Strategy Following COVID-19 Pandemic: A Tiered and Balanced Approach. Medical Care. PMID 33273293 DOI: 10.1097/MLR.0000000000001471  0.107
2021 McKnight RR, Ruffolo M, Wally MK, Seymour RB, Jeray K, Matuszewski P, Weinlein J, Hsu JR. Traumatic Arthrotomies: Do They All Need the Operating Room? Journal of Orthopaedic Trauma. PMID 34387570 DOI: 10.1097/BOT.0000000000002093  0.107
2016 Ko HW, Lee HH, Huo L, Xia W, Yang CC, Hsu JL, Li LY, Lai CC, Chan LC, Cheng CC, Labaff AM, Liao HW, Lim SO, Li CW, Wei Y, et al. GSK3β inactivation promotes the oncogenic functions of EZH2 and enhances methylation of H3K27 in human breast cancers. Oncotarget. PMID 27494834 DOI: 10.18632/oncotarget.11008  0.106
2018 Cheng AN, Lo YK, Lin YS, Tang TK, Hsu CH, Hsu JT, Lee AY. Identification of Novel Cdc7 Kinase Inhibitors as Anti-Cancer Agents that Target the Interaction with Dbf4 by the Fragment Complementation and Drug Repositioning Approach. Ebiomedicine. PMID 30293817 DOI: 10.1016/j.ebiom.2018.09.030  0.106
2022 Hsu JY, Chang CJ, Cheng JS. Survival, treatment regimens and medical costs of women newly diagnosed with metastatic triple-negative breast cancer. Scientific Reports. 12: 729. PMID 35031634 DOI: 10.1038/s41598-021-04316-2  0.106
2019 Lai MY, Hsu JF, Chu SM, Wu IH, Huang HR, Chiang MC, Fu RH, Tsai MH. Risk Factors and Outcomes of Recurrent Candidemia in Children: Relapse or Re-Infection? Journal of Clinical Medicine. 8. PMID 30654524 DOI: 10.3390/jcm8010099  0.106
2021 Huang WC, Fu PK, Chan MC, Chin CS, Huang WN, Lai KL, Wang JL, Hung WT, Wu YD, Hsieh CW, Wu MF, Chen YH, Hsu JY. Predictors of a Minimal Clinically Important Difference Following Omalizumab Treatment in Adult Patients With Severe Allergic Asthma. Frontiers in Medicine. 8: 762318. PMID 35047521 DOI: 10.3389/fmed.2021.762318  0.106
2021 Liu Y, Wang B, Tian H, Hsu JC. Rejoinder for discussions on correct and logical causal inference for binary and time-to-event outcomes in randomized controlled trials. Biometrical Journal. Biometrische Zeitschrift. PMID 34270810 DOI: 10.1002/bimj.202100089  0.105
2016 Sosale NG, Ivanovska II, Tsai RK, Swift J, Hsu JW, Alvey CM, Zoltick PW, Discher DE. "Marker of Self" CD47 on lentiviral vectors decreases macrophage-mediated clearance and increases delivery to SIRPA-expressing lung carcinoma tumors. Molecular Therapy. Methods & Clinical Development. 3: 16080. PMID 28053997 DOI: 10.1038/Mtm.2016.80  0.105
2012 Xie X, Li L, Xiao X, Guo J, Kong Y, Wu M, Liu W, Gao G, Hsu JL, Wei W, Hung MC, Xie X. Targeted expression of BikDD eliminates breast cancer with virtually no toxicity in noninvasive imaging models. Molecular Cancer Therapeutics. 11: 1915-24. PMID 22752427 DOI: 10.1158/1535-7163.Mct-12-0191  0.105
2012 Xie X, Li L, Xiao X, Guo J, Kong Y, Wu M, Liu W, Gao G, Hsu JL, Wei W, Hung MC, Xie X. Targeted expression of BikDD eliminates breast cancer with virtually no toxicity in noninvasive imaging models. Molecular Cancer Therapeutics. 11: 1915-24. PMID 22752427 DOI: 10.1158/1535-7163.Mct-12-0191  0.105
2012 Xie X, Li L, Xiao X, Guo J, Kong Y, Wu M, Liu W, Gao G, Hsu JL, Wei W, Hung MC, Xie X. Targeted expression of BikDD eliminates breast cancer with virtually no toxicity in noninvasive imaging models. Molecular Cancer Therapeutics. 11: 1915-24. PMID 22752427 DOI: 10.1158/1535-7163.Mct-12-0191  0.105
2012 Xie X, Li L, Xiao X, Guo J, Kong Y, Wu M, Liu W, Gao G, Hsu JL, Wei W, Hung MC, Xie X. Targeted expression of BikDD eliminates breast cancer with virtually no toxicity in noninvasive imaging models. Molecular Cancer Therapeutics. 11: 1915-24. PMID 22752427 DOI: 10.1158/1535-7163.Mct-12-0191  0.105
2012 Xie X, Li L, Xiao X, Guo J, Kong Y, Wu M, Liu W, Gao G, Hsu JL, Wei W, Hung MC, Xie X. Targeted expression of BikDD eliminates breast cancer with virtually no toxicity in noninvasive imaging models. Molecular Cancer Therapeutics. 11: 1915-24. PMID 22752427 DOI: 10.1158/1535-7163.Mct-12-0191  0.105
2012 Xie X, Li L, Xiao X, Guo J, Kong Y, Wu M, Liu W, Gao G, Hsu JL, Wei W, Hung MC, Xie X. Targeted expression of BikDD eliminates breast cancer with virtually no toxicity in noninvasive imaging models. Molecular Cancer Therapeutics. 11: 1915-24. PMID 22752427 DOI: 10.1158/1535-7163.Mct-12-0191  0.105
2021 Szmulewicz AG, Benson NM, Hsu J, Hernán MA, Öngür D. Effects of COVID-19 pandemic on mental health outcomes in a cohort of early psychosis patients. Early Intervention in Psychiatry. PMID 33432786 DOI: 10.1111/eip.13113  0.105
2017 Li CW, Lim SO, Hsu JL, Hung MC. Rational combination of immunotherapy for triple negative breast cancer treatment. Chinese Clinical Oncology. 6: 54. PMID 29129094 DOI: :10.21037/cco.2017.08.04  0.104
2021 Chang WF, Peng M, Hsu J, Xu J, Cho HC, Hsieh-Li HM, Liu JL, Lu CH, Sung LY. Effects of Survival Motor Neuron Protein on Germ Cell Development in Mouse and Human. International Journal of Molecular Sciences. 22. PMID 33440839 DOI: 10.3390/ijms22020661  0.104
2017 Juric D, Krop I, Ramanathan RK, Wilson TR, Ware JA, Sanabria Bohorquez S, Savage H, Sampath D, Salphati L, Lin R, Jin H, Parmar H, Hsu JY, Von Hoff DD, Baselga J. Phase I Dose Escalation Study of Taselisib (GDC-0032), an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors. Cancer Discovery. PMID 28331003 DOI: 10.1158/2159-8290.CD-16-1080  0.103
2009 Sher Y, Tzeng T, Kan S, Hsu J, Xie X, Han Z, Lin W, Li L, Hung M. Cancer targeted gene therapy of BikDD inhibits orthotopic lung cancer growth and improves long-term survival Oncogene. 28: 3286-3295. DOI: 10.1038/onc.2009.187  0.103
2009 Sher Y, Tzeng T, Kan S, Hsu J, Xie X, Han Z, Lin W, Li L, Hung M. Cancer targeted gene therapy of BikDD inhibits orthotopic lung cancer growth and improves long-term survival Oncogene. 28: 3286-3295. DOI: 10.1038/onc.2009.187  0.103
2009 Sher Y, Tzeng T, Kan S, Hsu J, Xie X, Han Z, Lin W, Li L, Hung M. Cancer targeted gene therapy of BikDD inhibits orthotopic lung cancer growth and improves long-term survival Oncogene. 28: 3286-3295. DOI: 10.1038/onc.2009.187  0.103
2009 Sher Y, Tzeng T, Kan S, Hsu J, Xie X, Han Z, Lin W, Li L, Hung M. Cancer targeted gene therapy of BikDD inhibits orthotopic lung cancer growth and improves long-term survival Oncogene. 28: 3286-3295. DOI: 10.1038/onc.2009.187  0.103
2009 Sher Y, Tzeng T, Kan S, Hsu J, Xie X, Han Z, Lin W, Li L, Hung M. Cancer targeted gene therapy of BikDD inhibits orthotopic lung cancer growth and improves long-term survival Oncogene. 28: 3286-3295. DOI: 10.1038/onc.2009.187  0.103
2009 Sher Y, Tzeng T, Kan S, Hsu J, Xie X, Han Z, Lin W, Li L, Hung M. Cancer targeted gene therapy of BikDD inhibits orthotopic lung cancer growth and improves long-term survival Oncogene. 28: 3286-3295. DOI: 10.1038/onc.2009.187  0.103
2009 Sher Y, Tzeng T, Kan S, Hsu J, Xie X, Han Z, Lin W, Li L, Hung M. Cancer targeted gene therapy of BikDD inhibits orthotopic lung cancer growth and improves long-term survival Oncogene. 28: 3286-3295. DOI: 10.1038/onc.2009.187  0.103
2009 Sher Y, Tzeng T, Kan S, Hsu J, Xie X, Han Z, Lin W, Li L, Hung M. Cancer targeted gene therapy of BikDD inhibits orthotopic lung cancer growth and improves long-term survival Oncogene. 28: 3286-3295. DOI: 10.1038/onc.2009.187  0.103
2009 Sher Y, Tzeng T, Kan S, Hsu J, Xie X, Han Z, Lin W, Li L, Hung M. Cancer targeted gene therapy of BikDD inhibits orthotopic lung cancer growth and improves long-term survival Oncogene. 28: 3286-3295. DOI: 10.1038/onc.2009.187  0.103
2009 Sher Y, Tzeng T, Kan S, Hsu J, Xie X, Han Z, Lin W, Li L, Hung M. Cancer targeted gene therapy of BikDD inhibits orthotopic lung cancer growth and improves long-term survival Oncogene. 28: 3286-3295. DOI: 10.1038/onc.2009.187  0.103
2009 Sher Y, Tzeng T, Kan S, Hsu J, Xie X, Han Z, Lin W, Li L, Hung M. Cancer targeted gene therapy of BikDD inhibits orthotopic lung cancer growth and improves long-term survival Oncogene. 28: 3286-3295. DOI: 10.1038/onc.2009.187  0.103
2009 Sher Y, Tzeng T, Kan S, Hsu J, Xie X, Han Z, Lin W, Li L, Hung M. Cancer targeted gene therapy of BikDD inhibits orthotopic lung cancer growth and improves long-term survival Oncogene. 28: 3286-3295. DOI: 10.1038/onc.2009.187  0.103
2009 Sher Y, Tzeng T, Kan S, Hsu J, Xie X, Han Z, Lin W, Li L, Hung M. Cancer targeted gene therapy of BikDD inhibits orthotopic lung cancer growth and improves long-term survival Oncogene. 28: 3286-3295. DOI: 10.1038/onc.2009.187  0.103
2009 Sher Y, Tzeng T, Kan S, Hsu J, Xie X, Han Z, Lin W, Li L, Hung M. Cancer targeted gene therapy of BikDD inhibits orthotopic lung cancer growth and improves long-term survival Oncogene. 28: 3286-3295. DOI: 10.1038/onc.2009.187  0.103
2009 Sher Y, Tzeng T, Kan S, Hsu J, Xie X, Han Z, Lin W, Li L, Hung M. Cancer targeted gene therapy of BikDD inhibits orthotopic lung cancer growth and improves long-term survival Oncogene. 28: 3286-3295. DOI: 10.1038/onc.2009.187  0.103
2009 Sher Y, Tzeng T, Kan S, Hsu J, Xie X, Han Z, Lin W, Li L, Hung M. Cancer targeted gene therapy of BikDD inhibits orthotopic lung cancer growth and improves long-term survival Oncogene. 28: 3286-3295. DOI: 10.1038/onc.2009.187  0.103
2017 Hsu JJ, Ziaeian B, Fonarow GC. Heart Failure With Mid-Range (Borderline) Ejection Fraction: Clinical Implications and Future Directions. Jacc. Heart Failure. PMID 29032140 DOI: 10.1016/J.Jchf.2017.06.013  0.103
2021 Krummen DE, Ho G, Hoffmayer KS, Schweis F, Baykaner T, Rogers AJ, Han FT, Hsu JC, Viswanathan MN, Wang PJ, Rappel WJ, Narayan SM. Electrical Substrate Ablation for Refractory Ventricular Fibrillation: Results of the AVATAR Study. Circulation. Arrhythmia and Electrophysiology. PMID 33550811 DOI: 10.1161/CIRCEP.120.008868  0.102
2017 Chan ML, Yu CC, Hsu JL, Leu WJ, Chan SH, Hsu LC, Liu SP, Ivantcova PM, Dogan Ö, Bräse S, Kudryavtsev KV, Guh JH. Enantiomerically pure β-dipeptide derivative induces anticancer activity against human hormone-refractory prostate cancer through both PI3K/Akt-dependent and -independent pathways. Oncotarget. 8: 96668-96683. PMID 29228561 DOI: 10.18632/Oncotarget.18040  0.102
2017 Chan ML, Yu CC, Hsu JL, Leu WJ, Chan SH, Hsu LC, Liu SP, Ivantcova PM, Dogan Ö, Bräse S, Kudryavtsev KV, Guh JH. Enantiomerically pure β-dipeptide derivative induces anticancer activity against human hormone-refractory prostate cancer through both PI3K/Akt-dependent and -independent pathways. Oncotarget. PMID 28586754 DOI: 10.18632/oncotarget.18040  0.102
2018 Castillo RC, Huang Y, Scharfstein D, Frey K, Bosse MJ, Pollak AN, Vallier HA, Archer KR, Hymes RA, Newcomb AB, MacKenzie EJ, Wegener S, Hsu JR, Karunakar MA, et al. Association Between 6-Week Postdischarge Risk Classification and 12-Month Outcomes After Orthopedic Trauma. Jama Surgery. e184824. PMID 30566192 DOI: 10.1001/Jamasurg.2018.4824  0.101
2017 Pang J, Hsu JP, Yeo TW, Leo YS, Lye DC. Diabetes, cardiac disorders and asthma as risk factors for severe organ involvement among adult dengue patients: A matched case-control study. Scientific Reports. 7: 39872. PMID 28045096 DOI: 10.1038/srep39872  0.101
2017 Hsu JT, Le PH, Kuo CF, Chiou MJ, Kuo CJ, Chen TH, Lin CJ, Chen JS, Yu HP, Yeh CN, Jan YY, Yeh TS. Imatinib dose escalation versus sunitinib as a second-line treatment against advanced gastrointestinal stromal tumors: A nationwide population-based cohort study. Oncotarget. 8: 71128-71137. PMID 29050348 DOI: 10.18632/oncotarget.16795  0.1
2017 Hsu JT, Le PH, Kuo CF, Chiou MJ, Kuo CJ, Chen TH, Lin CJ, Chen JS, Yu HP, Yeh CN, Jan YY, Yeh TS. Imatinib dose escalation versus sunitinib as a second-line treatment against advanced gastrointestinal stromal tumors: A nationwide population-based cohort study. Oncotarget. PMID 28423367 DOI: 10.18632/oncotarget.16795  0.1
2018 Huang CF, Yang SF, Chiou HL, Hsu WH, Hsu JC, Liu CJ, Hsieh YH. Licochalcone A inhibits the invasive potential of human glioma cells by targeting the MEK/ERK and ADAM9 signaling pathways. Food & Function. PMID 30465574 DOI: 10.1039/c8fo01643g  0.1
2018 Li CW, Lai YJ, Hsu JL, Hung MC. Activation of phagocytosis by immune checkpoint blockade. Frontiers of Medicine. PMID 30062558 DOI: 10.1007/s11684-018-0657-5  0.1
2019 Hsu JY, Liu AB. Anticoagulants for cancer-associated ischemic stroke. Ci Ji Yi Xue Za Zhi = Tzu-Chi Medical Journal. 31: 144-148. PMID 31258288 DOI: 10.4103/tcmj.tcmj_55_19  0.1
2016 Chang CH, Lin JW, Hsu J, Wu LC, Lai MS. Stent revascularization versus bypass surgery for peripheral artery disease in type 2 diabetic patients - an instrumental variable analysis. Scientific Reports. 6: 37177. PMID 27857178 DOI: 10.1038/srep37177  0.1
2020 Shemesh CS, Hsu JC, Hosseini I, Shen BQ, Rotte A, Twomey P, Girish S, Wu B. Personalized Cancer Vaccines: Clinical Landscape, Challenges, and Opportunities. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 33038322 DOI: 10.1016/j.ymthe.2020.09.038  0.1
2017 Hsu JS, Jaw TS, Yang CJ, Lin SF, Shih MP, Chou SH, Chong IW, Lin MY, Chiang IC. Convex border of peripheral non-small cell lung cancer on CT images as a potential indicator of pleural invasion. Medicine. 96: e7323. PMID 29049171 DOI: 10.1097/MD.0000000000007323  0.1
2020 Lin SY, Chang CF, Coumar MS, Chen PY, Kuo FM, Chen CH, Li MC, Lin WH, Kuo PC, Wang SY, Li AS, Lin CY, Yang CM, Yeh TK, Song JS, ... Hsu JTA, et al. Drug-like property optimization: Discovery of orally bioavailable quinazoline-based multi-targeted kinase inhibitors. Bioorganic Chemistry. 98: 103689. PMID 32171993 DOI: 10.1016/j.bioorg.2020.103689  0.1
2017 Liu KH, Hsu CH, Hsu JT, Tsai CY, Liu YY, Hwang TL, Yeh TS, Hung YS, Chou WC. A nomogram for predicting the probability of recurrence in patients with carcinomas located in the ampulla of Vater. Journal of Cancer. 8: 425-433. PMID 28261344 DOI: 10.7150/jca.17315  0.099
2010 Cheng X, Xia W, Yang JY, Hsu JL, Chou CK, Sun HL, Wyszomierski SL, Mills GB, Muller WJ, Yu D, Hung MC. Activation of p21(CIP1/WAF1) in mammary epithelium accelerates mammary tumorigenesis and promotes lung metastasis. Biochemical and Biophysical Research Communications. 403: 103-7. PMID 21040707 DOI: 10.1016/J.Bbrc.2010.10.126  0.099
2010 Cheng X, Xia W, Yang JY, Hsu JL, Chou CK, Sun HL, Wyszomierski SL, Mills GB, Muller WJ, Yu D, Hung MC. Activation of p21(CIP1/WAF1) in mammary epithelium accelerates mammary tumorigenesis and promotes lung metastasis. Biochemical and Biophysical Research Communications. 403: 103-7. PMID 21040707 DOI: 10.1016/J.Bbrc.2010.10.126  0.099
2010 Cheng X, Xia W, Yang JY, Hsu JL, Chou CK, Sun HL, Wyszomierski SL, Mills GB, Muller WJ, Yu D, Hung MC. Activation of p21(CIP1/WAF1) in mammary epithelium accelerates mammary tumorigenesis and promotes lung metastasis. Biochemical and Biophysical Research Communications. 403: 103-7. PMID 21040707 DOI: 10.1016/J.Bbrc.2010.10.126  0.099
2010 Cheng X, Xia W, Yang JY, Hsu JL, Chou CK, Sun HL, Wyszomierski SL, Mills GB, Muller WJ, Yu D, Hung MC. Activation of p21(CIP1/WAF1) in mammary epithelium accelerates mammary tumorigenesis and promotes lung metastasis. Biochemical and Biophysical Research Communications. 403: 103-7. PMID 21040707 DOI: 10.1016/J.Bbrc.2010.10.126  0.099
2010 Cheng X, Xia W, Yang JY, Hsu JL, Chou CK, Sun HL, Wyszomierski SL, Mills GB, Muller WJ, Yu D, Hung MC. Activation of p21(CIP1/WAF1) in mammary epithelium accelerates mammary tumorigenesis and promotes lung metastasis. Biochemical and Biophysical Research Communications. 403: 103-7. PMID 21040707 DOI: 10.1016/J.Bbrc.2010.10.126  0.099
2010 Cheng X, Xia W, Yang JY, Hsu JL, Chou CK, Sun HL, Wyszomierski SL, Mills GB, Muller WJ, Yu D, Hung MC. Activation of p21(CIP1/WAF1) in mammary epithelium accelerates mammary tumorigenesis and promotes lung metastasis. Biochemical and Biophysical Research Communications. 403: 103-7. PMID 21040707 DOI: 10.1016/J.Bbrc.2010.10.126  0.099
2010 Cheng X, Xia W, Yang JY, Hsu JL, Chou CK, Sun HL, Wyszomierski SL, Mills GB, Muller WJ, Yu D, Hung MC. Activation of p21(CIP1/WAF1) in mammary epithelium accelerates mammary tumorigenesis and promotes lung metastasis. Biochemical and Biophysical Research Communications. 403: 103-7. PMID 21040707 DOI: 10.1016/J.Bbrc.2010.10.126  0.099
2010 Cheng X, Xia W, Yang JY, Hsu JL, Chou CK, Sun HL, Wyszomierski SL, Mills GB, Muller WJ, Yu D, Hung MC. Activation of p21(CIP1/WAF1) in mammary epithelium accelerates mammary tumorigenesis and promotes lung metastasis. Biochemical and Biophysical Research Communications. 403: 103-7. PMID 21040707 DOI: 10.1016/J.Bbrc.2010.10.126  0.099
2010 Cheng X, Xia W, Yang JY, Hsu JL, Chou CK, Sun HL, Wyszomierski SL, Mills GB, Muller WJ, Yu D, Hung MC. Activation of p21(CIP1/WAF1) in mammary epithelium accelerates mammary tumorigenesis and promotes lung metastasis. Biochemical and Biophysical Research Communications. 403: 103-7. PMID 21040707 DOI: 10.1016/J.Bbrc.2010.10.126  0.099
2010 Cheng X, Xia W, Yang JY, Hsu JL, Chou CK, Sun HL, Wyszomierski SL, Mills GB, Muller WJ, Yu D, Hung MC. Activation of p21(CIP1/WAF1) in mammary epithelium accelerates mammary tumorigenesis and promotes lung metastasis. Biochemical and Biophysical Research Communications. 403: 103-7. PMID 21040707 DOI: 10.1016/J.Bbrc.2010.10.126  0.099
2010 Cheng X, Xia W, Yang JY, Hsu JL, Chou CK, Sun HL, Wyszomierski SL, Mills GB, Muller WJ, Yu D, Hung MC. Activation of p21(CIP1/WAF1) in mammary epithelium accelerates mammary tumorigenesis and promotes lung metastasis. Biochemical and Biophysical Research Communications. 403: 103-7. PMID 21040707 DOI: 10.1016/J.Bbrc.2010.10.126  0.099
2010 Cheng X, Xia W, Yang JY, Hsu JL, Chou CK, Sun HL, Wyszomierski SL, Mills GB, Muller WJ, Yu D, Hung MC. Activation of p21(CIP1/WAF1) in mammary epithelium accelerates mammary tumorigenesis and promotes lung metastasis. Biochemical and Biophysical Research Communications. 403: 103-7. PMID 21040707 DOI: 10.1016/J.Bbrc.2010.10.126  0.099
2010 Cheng X, Xia W, Yang JY, Hsu JL, Chou CK, Sun HL, Wyszomierski SL, Mills GB, Muller WJ, Yu D, Hung MC. Activation of p21(CIP1/WAF1) in mammary epithelium accelerates mammary tumorigenesis and promotes lung metastasis. Biochemical and Biophysical Research Communications. 403: 103-7. PMID 21040707 DOI: 10.1016/J.Bbrc.2010.10.126  0.099
2010 Cheng X, Xia W, Yang JY, Hsu JL, Chou CK, Sun HL, Wyszomierski SL, Mills GB, Muller WJ, Yu D, Hung MC. Activation of p21(CIP1/WAF1) in mammary epithelium accelerates mammary tumorigenesis and promotes lung metastasis. Biochemical and Biophysical Research Communications. 403: 103-7. PMID 21040707 DOI: 10.1016/J.Bbrc.2010.10.126  0.099
2010 Cheng X, Xia W, Yang JY, Hsu JL, Chou CK, Sun HL, Wyszomierski SL, Mills GB, Muller WJ, Yu D, Hung MC. Activation of p21(CIP1/WAF1) in mammary epithelium accelerates mammary tumorigenesis and promotes lung metastasis. Biochemical and Biophysical Research Communications. 403: 103-7. PMID 21040707 DOI: 10.1016/J.Bbrc.2010.10.126  0.099
2010 Cheng X, Xia W, Yang JY, Hsu JL, Chou CK, Sun HL, Wyszomierski SL, Mills GB, Muller WJ, Yu D, Hung MC. Activation of p21(CIP1/WAF1) in mammary epithelium accelerates mammary tumorigenesis and promotes lung metastasis. Biochemical and Biophysical Research Communications. 403: 103-7. PMID 21040707 DOI: 10.1016/J.Bbrc.2010.10.126  0.099
2010 Cheng X, Xia W, Yang JY, Hsu JL, Chou CK, Sun HL, Wyszomierski SL, Mills GB, Muller WJ, Yu D, Hung MC. Activation of p21(CIP1/WAF1) in mammary epithelium accelerates mammary tumorigenesis and promotes lung metastasis. Biochemical and Biophysical Research Communications. 403: 103-7. PMID 21040707 DOI: 10.1016/J.Bbrc.2010.10.126  0.099
2010 Cheng X, Xia W, Yang JY, Hsu JL, Chou CK, Sun HL, Wyszomierski SL, Mills GB, Muller WJ, Yu D, Hung MC. Activation of p21(CIP1/WAF1) in mammary epithelium accelerates mammary tumorigenesis and promotes lung metastasis. Biochemical and Biophysical Research Communications. 403: 103-7. PMID 21040707 DOI: 10.1016/J.Bbrc.2010.10.126  0.099
2010 Cheng X, Xia W, Yang JY, Hsu JL, Chou CK, Sun HL, Wyszomierski SL, Mills GB, Muller WJ, Yu D, Hung MC. Activation of p21(CIP1/WAF1) in mammary epithelium accelerates mammary tumorigenesis and promotes lung metastasis. Biochemical and Biophysical Research Communications. 403: 103-7. PMID 21040707 DOI: 10.1016/J.Bbrc.2010.10.126  0.099
2019 Franklin N, Hsu JR, Wilken J, McMenemy L, Ramasamy A, Stinner DJ. Advanced Functional Bracing in Lower Extremity Trauma: Bracing to Improve Function. Sports Medicine and Arthroscopy Review. 27: 107-111. PMID 31361720 DOI: 10.1097/Jsa.0000000000000259  0.099
2018 McQuade JL, Daniel CR, Hess KR, Mak C, Wang DY, Rai RR, Park JJ, Haydu LE, Spencer C, Wongchenko M, Lane S, Lee DY, Kaper M, McKean M, Beckermann KE, ... ... Hsu J, et al. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. The Lancet. Oncology. PMID 29449192 DOI: 10.1016/S1470-2045(18)30078-0  0.098
2018 Vazquez Guillamet C, Hsu JL, Dhillon G, Vazquez Guillamet R. Pulmonary Infections in Immunocompromised Hosts: Clinical. Journal of Thoracic Imaging. PMID 30048345 DOI: 10.1097/RTI.0000000000000351  0.098
2017 Shou H, Hsu JY, Xie D, Yang W, Roy J, Anderson AH, Landis JR, Feldman HI, Parsa A, Jepson C. Analytic Considerations for Repeated Measures of eGFR in Cohort Studies of CKD. Clinical Journal of the American Society of Nephrology : Cjasn. PMID 28751576 DOI: 10.2215/CJN.11311116  0.098
2019 Matsen FA, Whitson A, Jackins SE, Neradilek MB, Warme WJ, Hsu JE. Ream and run and total shoulder: patient and shoulder characteristics in five hundred forty-four concurrent cases. International Orthopaedics. PMID 31240359 DOI: 10.1007/s00264-019-04352-8  0.098
2020 Chawla SS, Whitson AJ, Schiffman CJ, Matsen FA, Hsu JE. Drivers of Lower Inpatient Hospital Costs and Greater Improvements in Health-Related Quality of Life for Patients Undergoing Total Shoulder and Ream-and-Run Arthroplasty. Journal of Shoulder and Elbow Surgery. PMID 33271324 DOI: 10.1016/j.jse.2020.10.030  0.098
2017 Bendell JC, Hochster H, Hart LL, Firdaus I, Mace JR, McFarlane JJ, Kozloff M, Catenacci D, Hsu JJ, Hack SP, Shames DS, Phan SC, Koeppen H, Cohn AL. A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer. The Oncologist. PMID 28209746 DOI: 10.1634/theoncologist.2016-0223  0.098
2019 Hsu JC, Wang CY, Su MM, Lin LY, Yang WS. Effect of Empagliflozin on Cardiac Function, Adiposity, and Diffuse Fibrosis in Patients with Type 2 Diabetes Mellitus. Scientific Reports. 9: 15348. PMID 31653956 DOI: 10.1038/s41598-019-51949-5  0.097
2020 Janko MR, Woo K, Hacker RI, Baril D, Bath J, Smeds MR, Kashyap VS, Szeberin Z, Magee G, Elsayed R, Wishy A, St John R, Beck A, Farber M, Motta F, ... ... Hsu J, et al. In-situ Bypass and Extra-anatomic Bypass Procedures Result in Similar Survival in Patients with Secondary Aorto-Enteric Fistulae. Journal of Vascular Surgery. PMID 32445832 DOI: 10.1016/J.Jvs.2020.04.515  0.097
2021 Hsu YJ, Lin JR, Hsu JF. Patient satisfaction, clinical outcomes and oral health-related quality of life after treatment with traditional and modified protocols for complete dentures. Journal of Dental Sciences. 16: 236-240. PMID 33384803 DOI: 10.1016/j.jds.2020.05.024  0.097
2011 Ding Q, Chang CJ, Xie X, Xia W, Yang JY, Wang SC, Wang Y, Xia J, Chen L, Cai C, Li H, Yen CJ, Kuo HP, Lee DF, Lang J, ... Hsu JL, et al. APOBEC3G promotes liver metastasis in an orthotopic mouse model of colorectal cancer and predicts human hepatic metastasis. The Journal of Clinical Investigation. 121: 4526-36. PMID 21985787 DOI: 10.1172/Jci45008  0.097
2011 Ding Q, Chang CJ, Xie X, Xia W, Yang JY, Wang SC, Wang Y, Xia J, Chen L, Cai C, Li H, Yen CJ, Kuo HP, Lee DF, Lang J, ... Hsu JL, et al. APOBEC3G promotes liver metastasis in an orthotopic mouse model of colorectal cancer and predicts human hepatic metastasis. The Journal of Clinical Investigation. 121: 4526-36. PMID 21985787 DOI: 10.1172/Jci45008  0.097
2011 Ding Q, Chang CJ, Xie X, Xia W, Yang JY, Wang SC, Wang Y, Xia J, Chen L, Cai C, Li H, Yen CJ, Kuo HP, Lee DF, Lang J, ... Hsu JL, et al. APOBEC3G promotes liver metastasis in an orthotopic mouse model of colorectal cancer and predicts human hepatic metastasis. The Journal of Clinical Investigation. 121: 4526-36. PMID 21985787 DOI: 10.1172/Jci45008  0.097
2018 Koshkin VS, Barata PC, Zhang T, George DJ, Atkins MB, Kelly WJ, Vogelzang NJ, Pal SK, Hsu J, Appleman LJ, Ornstein MC, Gilligan T, Grivas P, Garcia JA, Rini BI. Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma. Journal For Immunotherapy of Cancer. 6: 9. PMID 29378660 DOI: 10.1186/s40425-018-0319-9  0.097
2018 Morcos PN, Nueesch E, Jaminion F, Guerini E, Hsu JC, Bordogna W, Balas B, Mercier F. Exposure-response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer. Cancer Chemotherapy and Pharmacology. PMID 29748847 DOI: 10.1007/s00280-018-3597-5  0.097
2018 Sun LL, Yang RY, Li CW, Chen MK, Shao B, Hsu JM, Chan LC, Yang Y, Hsu JL, Lai YJ, Hung MC. Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing. American Journal of Cancer Research. 8: 1307-1316. PMID 30094103  0.097
2019 Chen MK, Du Y, Sun L, Hsu JL, Wang YH, Gao Y, Huang J, Hung MC. HOinduces nuclear transport of the receptor tyrosine kinase c-MET in breast cancer cells via a membrane-bounded retrograde trafficking mechanism. The Journal of Biological Chemistry. PMID 30962283 DOI: 10.1074/jbc.RA118.005953  0.097
2018 Aldaas OM, Malladi CL, Hsu JC. Catheter Ablation of Atrial Fibrillation in Patients With Heart Failure. The American Journal of Cardiology. PMID 30352662 DOI: 10.1016/j.amjcard.2018.09.013  0.097
2018 Huang WC, Lee CH, Wu MF, Huang CC, Hsu CH, Chen HC, Hsu JY, Huang CC. Clinical features, bacteriology of endotracheal aspirates and treatment outcomes of patients with chronic obstructive pulmonary disease and community-acquired pneumonia in an intensive care unit in Taiwan with an emphasis on eosinophilia versus non-eosinophilia: a retrospective case-control study. Bmj Open. 8: e020341. PMID 30206074 DOI: 10.1136/bmjopen-2017-020341  0.097
2019 Lin JL, Wu TJ, Chen CP, Hsu JC, Ueng KC, Kuo JY, Chen MC, Yeh KH, Chang KC, Lu YY, Shyu KG, Wen MS, Chen SA, Hsieh MH, Tseng WK, et al. Observational study of dronedarone in Taiwanese patients with atrial fibrillation. Journal of the Formosan Medical Association = Taiwan Yi Zhi. PMID 31023506 DOI: 10.1016/j.jfma.2019.03.009  0.097
2017 Hsu JR, Owens JG, DeSanto J, Fergason JR, Kuhn KM, Potter BK, Stinner DJ, Sheu RG, Waggoner SL, Wilken JM, Huang Y, Scharfstein DO, MacKenzie EJ. Patient Response to an Integrated Orthotic and Rehabilitation Initiative for Traumatic Injuries: The PRIORITI-MTF Study. Journal of Orthopaedic Trauma. 31: S56-S62. PMID 28323803 DOI: 10.1097/Bot.0000000000000795  0.097
2020 Chu SM, Hsu JF, Lai MY, Huang HR, Chiang MC, Fu RH, Tsai MH. Risk Factors of Initial Inappropriate Antibiotic Therapy and the Impacts on Outcomes of Neonates with Gram-Negative Bacteremia. Antibiotics (Basel, Switzerland). 9. PMID 32340241 DOI: 10.3390/antibiotics9040203  0.096
2020 Liou SF, Nguyen TTN, Hsu JH, Sulistyowati E, Huang SE, Wu BN, Lin MC, Yeh JL. The Preventive Effects of Xanthohumol on Vascular Calcification Induced by Vitamin D Plus Nicotine. Antioxidants (Basel, Switzerland). 9. PMID 33036258 DOI: 10.3390/antiox9100956  0.096
2020 Chang WF, Xu J, Lin TY, Hsu J, Hsieh-Li HM, Hwu YM, Liu JL, Lu CH, Sung LY. Survival Motor Neuron Protein Participates in Mouse Germ Cell Development and Spermatogonium Maintenance. International Journal of Molecular Sciences. 21. PMID 31991812 DOI: 10.3390/ijms21030794  0.096
2018 Chang SC, Liu KH, Hung CY, Tsai CY, Hsu JT, Yeh TS, Chen JS, Kuo YC, Hung YS, Chou WC. Adjuvant Chemotherapy Improves Survival in Stage III Gastric Cancer after D2 Surgery. Journal of Cancer. 9: 81-91. PMID 29290772 DOI: 10.7150/jca.21989  0.096
2020 Cao TTB, Wu KC, Hsu JL, Chang CS, Chou C, Lin CY, Liao YM, Lin PC, Yang LY, Lin HW. Effects of Non-insulin Anti-hyperglycemic Agents on Gut Microbiota: A Systematic Review on Human and Animal Studies. Frontiers in Endocrinology. 11: 573891. PMID 33071980 DOI: 10.3389/fendo.2020.573891  0.096
2018 Cooper JC, Rouster-Stevens K, Wright TB, Hsu JJ, Klein-Gitelman MS, Ardoin SP, Schanberg LE, Brunner HI, Eberhard BA, Wagner-Weiner L, Mehta J, Haines K, McCurdy DK, Phillips TA, Huang Z, et al. Pilot study comparing the childhood arthritis and rheumatology research alliance consensus treatment plans for induction therapy of juvenile proliferative lupus nephritis. Pediatric Rheumatology Online Journal. 16: 65. PMID 30348175 DOI: 10.1186/s12969-018-0279-0  0.095
2020 Powell RJ, Brown KR, Davies MG, Hart JP, Hsu JH, Johnson B, Makaroun M, Schanzer A, Shutze W, Weaver FA, White J. The Value of the Modern Vascular Surgeon to the Health Care System: A Report from the Society for Vascular Surgery Valuation Work Group. Journal of Vascular Surgery. PMID 32585182 DOI: 10.1016/j.jvs.2020.05.056  0.095
2021 Yang R, Sun L, Li CF, Wang YH, Yao J, Li H, Yan M, Chang WC, Hsu JM, Cha JH, Hsu JL, Chou CW, Sun X, Deng Y, Chou CK, et al. Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy. Nature Communications. 12: 832. PMID 33547304 DOI: 10.1038/s41467-021-21099-2  0.095
2021 Sung CJ, Wang SX, Hsu JF, Yu RP, Wong AK. Current Understanding of Pathological Mechanisms of Lymphedema. Advances in Wound Care. PMID 34521256 DOI: 10.1089/wound.2021.0041  0.095
2021 Hsu JY, Liu PP, Liu AB, Lin SM, Huang HK, Loh CH. Lower Risk of Dementia in Patients With Atrial Fibrillation Taking Non-Vitamin K Antagonist Oral Anticoagulants: A Nationwide Population-Based Cohort Study. Journal of the American Heart Association. e016437. PMID 33586465 DOI: 10.1161/JAHA.120.016437  0.095
2021 Lin C, Chu SM, Hsu JF, Hsu CC, Chang YL, Lien R, Cheng SW, Chiang MC. Delivery management of suspected or confirmed COVID-19 positive mothers. Pediatrics and Neonatology. PMID 34272199 DOI: 10.1016/j.pedneo.2021.06.004  0.095
2017 Yang CJ, Tsai MJ, Hung JY, Lee MH, Tsai YM, Tsai YC, Hsu JF, Liu TC, Huang MS, Chong IW. The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations. Bmc Pharmacology & Toxicology. 18: 82. PMID 29237484 DOI: 10.1186/s40360-017-0190-1  0.095
2021 Stein-Merlob AF, Hsu JJ, Colton B, Berg CJ, Ferreira A, Price MM, Wainberg Z, Baas AS, Deng MC, Parikh RV, Yang EH. Keeping immune checkpoint inhibitor myocarditis in check: advanced circulatory mechanical support as a bridge to recovery. Esc Heart Failure. PMID 34390221 DOI: 10.1002/ehf2.13545  0.094
2018 Chandrasekar P, Sirohi B, Seibel NL, Hsu JW, Azie N, Wu C, Ruhnke M. Efficacy of micafungin for treatment of invasive candidiasis and candidaemia in patients with neutropenia. Mycoses. PMID 29364548 DOI: 10.1111/myc.12748  0.094
2018 Li Z, Ju X, Lee K, Clarke C, Hsu JL, Abadir E, Bryant CE, Pears S, Sunderland N, Heffernan S, Hennessy A, Lo TH, Pietersz GA, Kupresanin F, Fromm PD, et al. CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma. Haematologica. PMID 29351987 DOI: 10.3324/haematol.2017.178384  0.094
2018 Yang WH, Cha JH, Xia W, Lee HH, Chan LC, Wang YN, Hsu JL, Ren G, Hung MC. Juxtacrine signaling inhibits antitumor immunity by upregulating PD-L1 expression. Cancer Research. PMID 29789418 DOI: 10.1158/0008-5472.CAN-18-0040  0.094
2018 Tang CS, Zhuang X, Lam WY, Ngan ES, Hsu JS, Michelle YU, Man-Ting SO, Cherny SS, Ngo ND, Sham PC, Tam PK, Garcia-Barcelo MM. Uncovering the genetic lesions underlying the most severe form of Hirschsprung disease by whole-genome sequencing. European Journal of Human Genetics : Ejhg. PMID 29483666 DOI: 10.1038/S41431-018-0129-Z  0.094
2020 Koff A, Laurent-Rolle M, Hsu JC, Malinis M. Prolonged incubation of SARS-CoV-2 in a Patient on Rituximab Therapy. Infection Control and Hospital Epidemiology. 1-10. PMID 33023685 DOI: 10.1017/ice.2020.1239  0.093
2020 Chuang HH, Hsu JF, Chang HL, Wang PH, Wei PJ, Wu DW, Huang MS, Hsiao M, Yang CJ. Pin1 coordinates HDAC6 upregulation with cell migration in lung cancer cells. International Journal of Medical Sciences. 17: 2635-2643. PMID 33162791 DOI: 10.7150/ijms.50097  0.093
2018 Yang Y, Li CW, Chan LC, Wei Y, Hsu JM, Xia W, Cha JH, Hou J, Hsu JL, Sun L, Hung MC. Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth. Cell Research. PMID 29959401 DOI: 10.1038/s41422-018-0060-4  0.093
2020 Chen HY, Wang ML, Laurent B, Hsu CH, Chen MT, Lin LT, Shen J, Chang WC, Hsu J, Hung MC, Chen YW, Huang PI, Yang YP, Li CP, Ma HI, et al. Musashi-1 promotes stress-induced tumor progression through recruitment of AGO2. Theranostics. 10: 201-217. PMID 31903115 DOI: 10.7150/thno.35895  0.093
2018 Hsu J, de la Fuente M, Radermacher K. Calculation of impingement-free combined cup and stem alignments based on the patient-specific pelvic tilt. Journal of Biomechanics. PMID 30447800 DOI: 10.1016/j.jbiomech.2018.10.020  0.093
2021 Goehler A, Hsu TH, Seiglie JA, Siedner MJ, Lo J, Triant V, Hsu J, Foulkes A, Bassett I, Khorasani R, Wexler DJ, Szolovits P, Meigs JB, Manne-Goehler J. Visceral Adiposity and Severe COVID-19 Disease: Application of an Artificial Intelligence Algorithm to Improve Clinical Risk Prediction. Open Forum Infectious Diseases. 8: ofab275. PMID 34258315 DOI: 10.1093/ofid/ofab275  0.093
2019 Kiyuna T, Tome Y, Miyake K, Murakami T, Oshiro H, Igarashi K, Kawaguchi K, Hsu J, Singh M, Li Y, Nelson S, Bouvet M, Singh SR, Kanaya F, Hoffman RM. Eribulin Suppressed Cisplatinum- and Doxorubicin-resistant Recurrent Lung Metastatic Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model. Anticancer Research. 39: 4775-4779. PMID 31519578 DOI: 10.21873/anticanres.13661  0.093
2017 Liu HD, Ahn KW, Hu ZH, Hamadani M, Nishihori T, Wirk B, Beitinjaneh A, Rizzieri D, Grunwald MR, Sabloff M, Olsson RF, Bajel A, Bredeson C, Daly A, Inamoto Y, ... ... Hsu JW, et al. Allogeneic Hematopoietic Cell Transplant for Adult Chronic Myelomonocytic Leukemia. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 28115276 DOI: 10.1016/j.bbmt.2017.01.078  0.092
2020 Reed M, Huang J, Brand R, Graetz I, Jaffe MG, Ballard D, Neugebauer R, Fireman B, Hsu J. Inpatient-outpatient shared electronic health records: telemedicine and laboratory follow-up after hospital discharge. The American Journal of Managed Care. 26: e327-e332. PMID 33094945 DOI: 10.37765/ajmc.2020.88506  0.092
2022 Moran LV, Tsang ES, Ongur D, Hsu J, Choi MY. Geographical variation in hospitalization for psychosis associated with cannabis use and cannabis legalization in the United States: Submit to: Psychiatry Research. Psychiatry Research. 308: 114387. PMID 35016118 DOI: 10.1016/j.psychres.2022.114387  0.092
2018 Bergerot CD, Clark KL, Ashing KT, Bergerot PG, Obenchain R, Dizman N, Hsu J, Philip E, Loscalzo M, Pal SK. Biopsychosocial distress and clinical outcome in metastatic renal cell carcinoma. Palliative & Supportive Care. 1-3. PMID 29911518 DOI: 10.1017/S1478951518000342  0.092
2021 Hsu JF, Chu SM, Liao CC, Wang CJ, Wang YS, Lai MY, Wang HC, Huang HR, Tsai MH. Nanotechnology and Nanocarrier-Based Drug Delivery as the Potential Therapeutic Strategy for Glioblastoma Multiforme: An Update. Cancers. 13. PMID 33430494 DOI: 10.3390/cancers13020195  0.092
2014 Xie X, Kong Y, Tang H, Yang L, Hsu JL, Hung MC. Targeted BikDD expression kills androgen-dependent and castration-resistant prostate cancer cells. Molecular Cancer Therapeutics. 13: 1813-25. PMID 24785255 DOI: 10.1158/1535-7163.MCT-13-1004  0.092
2014 Xie X, Kong Y, Tang H, Yang L, Hsu JL, Hung MC. Targeted BikDD expression kills androgen-dependent and castration-resistant prostate cancer cells. Molecular Cancer Therapeutics. 13: 1813-25. PMID 24785255 DOI: 10.1158/1535-7163.MCT-13-1004  0.092
2014 Xie X, Kong Y, Tang H, Yang L, Hsu JL, Hung MC. Targeted BikDD expression kills androgen-dependent and castration-resistant prostate cancer cells. Molecular Cancer Therapeutics. 13: 1813-25. PMID 24785255 DOI: 10.1158/1535-7163.MCT-13-1004  0.092
2019 Hsu JC, Lin JY, Lin PC, Lee YC. Comprehensive value assessment of drugs using a multi-criteria decision analysis: An example of targeted therapies for metastatic colorectal cancer treatment. Plos One. 14: e0225938. PMID 31830075 DOI: 10.1371/journal.pone.0225938  0.092
2020 Chung WS, Le PH, Kuo CJ, Chen TH, Kuo CF, Chiou MJ, Chou WC, Yeh TS, Hsu JT. Impact of Metformin Use on Survival in Patients with Gastric Cancer and Diabetes Mellitus Following Gastrectomy. Cancers. 12. PMID 32717852 DOI: 10.3390/cancers12082013  0.091
2010 Cheng X, Xia W, Yang JY, Hsu JL, Lang JY, Chou CK, Du Y, Sun HL, Wyszomierski SL, Mills GB, Muller WJ, Yu D, Hung MC. Activation of murine double minute 2 by Akt in mammary epithelium delays mammary involution and accelerates mammary tumorigenesis. Cancer Research. 70: 7684-9. PMID 20841468 DOI: 10.1158/0008-5472.Can-09-3231  0.091
2017 Bousmail D, Amrein L, Fakhoury JJ, Fakih HH, Hsu JCC, Panasci L, Sleiman HF. Precision spherical nucleic acids for delivery of anticancer drugs. Chemical Science. 8: 6218-6229. PMID 28989655 DOI: 10.1039/C7Sc01619K  0.091
2019 Yan Y, Wongchenko MJ, Robert C, Larkin J, Ascierto PA, Dreno B, Maio M, Garbe C, Chapman PB, Sosman JA, Shi Z, Koeppen H, Hsu JJ, Chang I, Caro I, et al. Genomic features of exceptional response in vemurafenib ± cobimetinib-treated patients with BRAFV600-mutated metastatic melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30824584 DOI: 10.1158/1078-0432.CCR-18-0720  0.091
2021 Ocher RA, Padilla E, Hsu JC, Taub PR. Clinical and Laboratory Improvement in Hyperadrenergic Postural Orthostatic Tachycardia Syndrome (POTS) after COVID-19 Infection. Case Reports in Cardiology. 2021: 7809231. PMID 34471549 DOI: 10.1155/2021/7809231  0.091
2019 Hsu JL, Cheng MY, Liao MF, Hsu HC, Weng YC, Chang KH, Chang HS, Kuo HC, Huang CC, Lyu RK, Lin KJ, Ro LS. A comparison between spinal cord infarction and neuromyelitis optica spectrum disorders: Clinical and MRI studies. Scientific Reports. 9: 7435. PMID 31092838 DOI: 10.1038/s41598-019-43606-8  0.09
2018 Mariscal AM, Kakizawa S, Hsu JY, Tanaka K, González-González L, Broto A, Querol E, Lluch-Senar M, Piñero-Lambea C, Sun L, Weyman PD, Wise KS, Merryman C, Tse G, Moore AJ, et al. Tuning Gene Activity by Inducible and Targeted Regulation of Gene Expression in Minimal Bacterial Cells. Acs Synthetic Biology. PMID 29786424 DOI: 10.1021/Acssynbio.8B00028  0.09
2016 Abdallah H, Hsu JC, Lu P, Fettner S, Zhang X, Douglass W, Bao M, Rowell L, Burmester GR, Kivitz A. Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From Two Randomized Controlled Trials: SUMMACTA and BREVACTA. Journal of Clinical Pharmacology. PMID 27599663 DOI: 10.1002/jcph.826  0.09
2020 Berkson JD, Slichter CK, DeBerg HA, Delaney MA, Woodward-Davis AS, Maurice NJ, Lwo Y, Ko A, Hsu J, Chiu YW, Linsley PS, Dixon D, Prlic M. Inflammatory Cytokines Induce Sustained CTLA-4 Cell Surface Expression on Human MAIT Cells. Immunohorizons. 4: 14-22. PMID 31974109 DOI: 10.4049/immunohorizons.1900061  0.09
2017 Chen CT, Chen YC, Du Y, Han Z, Ying H, Bouchard RR, Hsu JL, Hsu JM, Mitcham TM, Chen MK, Sun HL, Chang SS, Li D, Chang P, DePinho RA, et al. A tumor vessel-targeting fusion protein elicits a chemotherapeutic bystander effect in pancreatic ductal adenocarcinoma. American Journal of Cancer Research. 7: 657-672. PMID 28401019  0.09
2016 Holena DN, Wiebe DJ, Carr BG, Hsu JY, Sperry JL, Peitzman AB, Reilly PM. Lead-Time Bias and Interhospital Transfer after Injury: Trauma Center Admission Vital Signs Underpredict Mortality in Transferred Trauma Patients. Journal of the American College of Surgeons. PMID 27993698 DOI: 10.1016/j.jamcollsurg.2016.11.016  0.09
2020 Tsai CY, Lin TA, Huang SC, Hsu JT, Yeh CN, Chen TC, Chiu CT, Chen JS, Yeh TS. Is Adjuvant Chemotherapy Necessary for Patients with Deficient Mismatch Repair Gastric Cancer?-Autophagy Inhibition Matches the Mismatched. The Oncologist. PMID 32058649 DOI: 10.1634/theoncologist.2019-0419  0.09
2018 Lin HM, Xu H, Ding Y, Hsu JC. Correct and logical inference on efficacy in subgroups and their mixture for binary outcomes. Biometrical Journal. Biometrische Zeitschrift. PMID 30353566 DOI: 10.1002/Bimj.201800002  0.09
2017 Chen TH, Hsu JH, Jong YJ. Noninvasive airway approaches for acute neuromuscular respiratory failure in emergency departments. Pediatric Pulmonology. 52: E55-E57. PMID 28941227 DOI: 10.1002/ppul.23693  0.089
2020 Tsai YS, Hsu JH, Lin DP, Chang HH, Chang WJ, Chen YL, Chen CC. Safety Assessment of HEA-Enriched Mycelium: A Randomized Clinical Trial. Journal of the American College of Nutrition. 1-6. PMID 32702252 DOI: 10.1080/07315724.2020.1743211  0.089
2017 Meneses-Lorente G, McIntyre C, Hsu JC, Thomas M, Jacob W, Adessi C, Weisser M. Accelerating drug development by efficiently using emerging PK/PD data from an adaptable entry-into-human trial: example of lumretuzumab. Cancer Chemotherapy and Pharmacology. PMID 28497320 DOI: 10.1007/s00280-017-3328-3  0.089
2017 Akers SR, Panchal V, Ho VB, Beache GM, Brown RKJ, Ghoshhajra BB, Greenberg SB, Hsu JY, Kicska GA, Min JK, Stillman AE, Stojanovska J, Abbara S, Jacobs JE. ACR Appropriateness Criteria(®) Chronic Chest Pain-High Probability of Coronary Artery Disease. Journal of the American College of Radiology : Jacr. 14: S71-S80. PMID 28473096 DOI: 10.1016/j.jacr.2017.01.034  0.089
2018 Chou YT, Hsu FF, Hu DY, Chen YC, Hsu YH, Hsu JT, Chau LY. Identification of danthron as an isoform-specific inhibitor of HEME OXYGENASE-1/cytochrome P450 reductase interaction with anti-tumor activity. Journal of Biomedical Science. 25: 6. PMID 29361943 DOI: 10.1186/S12929-018-0411-Y  0.089
2017 Nishimura M, Hsu JC. Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and End-Stage Renal Disease. The American Journal of Cardiology. PMID 29132650 DOI: 10.1016/j.amjcard.2017.09.030  0.089
2017 Stinner DJ, Wenke JC, Ficke JR, Gordon W, Toledano J, Carlini AR, Scharfstein DO, MacKenzie EJ, Bosse MJ, Hsu JR. Military and Civilian Collaboration: The Power of Numbers. Military Medicine. 182: 10-17. PMID 28291446 DOI: 10.7205/Milmed-D-16-00138  0.089
2016 Leu WJ, Swain SP, Chan SH, Hsu JL, Liu SP, Chan ML, Yu CC, Hsu LC, Chou YL, Chang WL, Hou DR, Guh JH. Non-immunosuppressive triazole-based small molecule induces anticancer activity against human hormone-refractory prostate cancers: the role in inhibition of PI3K/AKT/mTOR and c-Myc signaling pathways. Oncotarget. PMID 27769069 DOI: 10.18632/oncotarget.12765  0.089
2016 Chang Hsu Y, Selvaraj Coumar M, Wang WC, Shiao HY, Ke YY, Lin WH, Kuo CC, Chang CW, Kuo FM, Chen PY, Wang SY, Li AS, Chen CH, Kuo PC, Chen CP, ... ... Hsu JT, et al. Discovery of BPR1K871, a quinazoline based, multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation. Oncotarget. PMID 27863392 DOI: 10.18632/oncotarget.13369  0.088
2017 Hsieh HC, Hsu JC, Lu CY. 10-year trends in statin utilization in Taiwan: a retrospective study using Taiwan's National Health Insurance Research Database. Bmj Open. 7: e014150. PMID 28515189 DOI: 10.1136/bmjopen-2016-014150  0.088
2021 He YJ, Lin MH, Hsu JL, Cheng BR, Chen TJ, Hwang SJ. Overview of the Motivation of Advance Care Planning: A Study from a Medical Center in Taiwan. International Journal of Environmental Research and Public Health. 18. PMID 33430302 DOI: 10.3390/ijerph18020417  0.088
2020 Koelmeyer L, Gaitatzis K, Ridner SH, Boyages J, Nelms J, Hughes TM, Elder E, French J, Ngui N, Hsu J, Stolldorf D. Implementing a prospective surveillance and early intervention model of care for breast cancer-related lymphedema into clinical practice: application of the RE-AIM framework. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. PMID 32613370 DOI: 10.1007/S00520-020-05597-5  0.088
2020 Tovmassian D, Hameed AM, Ly J, Pathmanathan N, Devadas M, Gomez D, Hsu JM. Process measure aimed at reducing time to haemorrhage control: outcomes associated with Code Crimson activation in exsanguinating truncal trauma. Anz Journal of Surgery. PMID 32048430 DOI: 10.1111/ans.15650  0.088
2021 Hsu J, Liu CH, Wei JC. American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 3: Comment on the Article by Mikuls et al. Arthritis & Rheumatology (Hoboken, N.J.). PMID 34105903 DOI: 10.1002/art.41889  0.088
2017 Hsu JL, Tjarks BJ, Berg A, Oliver T. Disseminated Blastomycosis Mimicking Malignancy. South Dakota Medicine : the Journal of the South Dakota State Medical Association. 70: 167-171. PMID 28813733  0.088
2016 Lim SO, Li CW, Xia W, Cha JH, Chan LC, Wu Y, Chang SS, Lin WC, Hsu JM, Hsu YH, Kim T, Chang WC, Hsu JL, Yamaguchi H, Ding Q, et al. Deubiquitination and Stabilization of PD-L1 by CSN5. Cancer Cell. PMID 27866850 DOI: 10.1016/J.Ccell.2016.10.010  0.088
2021 Orfali N, Jhanwar Y, Koo C, Pasciolla M, Baldo M, Cuvilly E, Furman R, Gergis U, Greenberg J, Guarneri D, Hsu JM, Leonard JP, Mark T, Mayer S, Maignan K, et al. Sequential intensive chemotherapy followed by autologous or allogeneic transplantation for refractory lymphoma. Leukemia & Lymphoma. 1-15. PMID 33586581 DOI: 10.1080/10428194.2021.1881516  0.088
2021 Yeh YT, Hsu JC, Liao PC, Li AH, Liu YH, Chen KC, Chuang W, Ke SR, Chiu YW, Wu YW. Modulators of Mortality Benefit From Peri-Angioplasty Adjunctive Tirofiban in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Circulation Journal : Official Journal of the Japanese Circulation Society. PMID 33441492 DOI: 10.1253/circj.CJ-20-0228  0.087
2020 Hsu J, Qin X, Mirabelli MC, Flanders WD. Medicaid Expansion, Health Insurance Coverage, and Cost Barriers to Care Among Low-Income Adults with Asthma: The Adult Asthma Call-Back Survey. The Journal of Asthma : Official Journal of the Association For the Care of Asthma. 1-15. PMID 32730723 DOI: 10.1080/02770903.2020.1804577  0.087
2020 Aldaas OM, Lupercio F, Darden D, Mylavarapu PS, Malladi CL, Han FT, Hoffmayer KS, Krummen D, Ho G, Raissi F, Birgersdotter-Green U, Feld GK, Hsu JC. Meta-Analysis of the Usefulness of Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure with Preserved Ejection Fraction. The American Journal of Cardiology. PMID 33290688 DOI: 10.1016/j.amjcard.2020.11.039  0.087
2017 Hsu JT, Liao JA, Chuang HC, Chen TD, Chen TH, Kuo CJ, Lin CJ, Chou WC, Yeh TS, Jan YY. Palliative gastrectomy is beneficial in selected cases of metastatic gastric cancer. Bmc Palliative Care. 16: 19. PMID 28288593 DOI: 10.1186/s12904-017-0192-1  0.087
2018 Hsu JC, Lin JY, Hsu MY, Lin PC. Effectiveness and safety of immune checkpoint inhibitors: A retrospective study in Taiwan. Plos One. 13: e0202725. PMID 30142174 DOI: 10.1371/journal.pone.0202725  0.087
2017 Singh AD, Parmar S, Patel K, Shah S, Shore T, Gergis U, Mayer S, Phillips A, Hsu JM, Niesvizky R, Mark TM, Pearse R, Rossi A, van Besien K. Granulocyte Colony-Stimulating Factor Use after Autologous Peripheral Blood Stem Cell Transplantation: Comparison of Two Practices. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 29061534 DOI: 10.1016/j.bbmt.2017.10.026  0.087
2012 Wang Y, Ding Q, Yen CJ, Xia W, Izzo JG, Lang JY, Li CW, Hsu JL, Miller SA, Wang X, Lee DF, Hsu JM, Huo L, Labaff AM, Liu D, et al. The crosstalk of mTOR/S6K1 and Hedgehog pathways. Cancer Cell. 21: 374-87. PMID 22439934 DOI: 10.1016/j.ccr.2011.12.028  0.087
2019 Saatcioglu HD, Kano M, Horn H, Zhang L, Samore W, Nagykery N, Meinsohn MC, Hyun M, Suliman R, Poulo J, Hsu J, Sacha C, Wang D, Gao G, Lage K, et al. Single-cell sequencing of neonatal uterus reveals an endometrial progenitor indispensable for fertility. Elife. 8. PMID 31232694 DOI: 10.7554/Elife.46349.001  0.087
2017 Huang WR, Chi PI, Chiu HC, Hsu JL, Nielsen BL, Liao TL, Liu HJ. Avian reovirus p17 and σA act cooperatively to downregulate Akt by suppressing mTORC2 and CDK2/cyclin A2 and upregulating proteasome PSMB6. Scientific Reports. 7: 5226. PMID 28701787 DOI: 10.1038/S41598-017-05510-X  0.086
2022 Schiffman CJ, Mills ZD, Hsu JE, Whitson AJ, Matsen Iii FA. Factors associated with failure of surgical revision and IV antibiotics to resolve Cutibacterium periprosthetic infection of the shoulder. International Orthopaedics. PMID 35031818 DOI: 10.1007/s00264-021-05259-z  0.086
2016 Fischer MJ, Hsu JY, Lora CM, Ricardo AC, Anderson AH, Bazzano L, Cuevas MM, Hsu CY, Kusek JW, Renteria A, Ojo AO, Raj DS, Rosas SE, Pan Q, Yaffe K, et al. CKD Progression and Mortality among Hispanics and Non-Hispanics. Journal of the American Society of Nephrology : Jasn. PMID 27151925 DOI: 10.1681/ASN.2015050570  0.086
2004 Baserga M, Bertolotto C, Maclennan NK, Hsu JL, Pham T, Laksana GS, Lane RH. Uteroplacental insufficiency decreases small intestine growth and alters apoptotic homeostasis in term intrauterine growth retarded rats. Early Human Development. 79: 93-105. PMID 15324990 DOI: 10.1016/j.earlhumdev.2004.04.015  0.086
2004 Baserga M, Bertolotto C, Maclennan NK, Hsu JL, Pham T, Laksana GS, Lane RH. Uteroplacental insufficiency decreases small intestine growth and alters apoptotic homeostasis in term intrauterine growth retarded rats. Early Human Development. 79: 93-105. PMID 15324990 DOI: 10.1016/j.earlhumdev.2004.04.015  0.086
2004 Baserga M, Bertolotto C, Maclennan NK, Hsu JL, Pham T, Laksana GS, Lane RH. Uteroplacental insufficiency decreases small intestine growth and alters apoptotic homeostasis in term intrauterine growth retarded rats. Early Human Development. 79: 93-105. PMID 15324990 DOI: 10.1016/j.earlhumdev.2004.04.015  0.086
2019 Hsu JC, Birnie D, Stadler RW, Cerkvenik J, Feld GK, Birgersdotter-Green U. Adaptive Cardiac Resynchronization Therapy is Associated with Decreased Risk of Incident Atrial Fibrillation Compared to Standard Biventricular Pacing: A Real-World Analysis of 37,450 Patients Followed by Remote Monitoring. Heart Rhythm. PMID 31102750 DOI: 10.1016/j.hrthm.2019.05.012  0.086
2016 Chang CD, Lin PY, Hsu JL, Shih WL. Ursolic Acid Suppresses Hepatitis B Virus X Protein-mediated Autophagy and Chemotherapeutic Drug Resistance. Anticancer Research. 36: 5097-5107. PMID 27798869  0.086
2020 Liao CC, Tsai MH, Lai SH, Lai MY, Chu SM, Huang HR, Hsu KH, Chiang MC, Fu RH, Hsu JF. Safety and clinical application of nonbronchoscopic bronchoalveolar lavage in preterm neonates with clinical ventilator-associated pneumonia. Pediatrics and Neonatology. PMID 33413988 DOI: 10.1016/j.pedneo.2020.11.008  0.085
2018 Graetz I, Huang J, Brand R, Hsu J, Reed ME. Mobile-accessible personal health records increase the frequency and timeliness of PHR use for patients with diabetes. Journal of the American Medical Informatics Association : Jamia. PMID 30358866 DOI: 10.1093/Jamia/Ocy129  0.085
2018 Hsu CP, Lee LY, Hsu JT, Hsu YP, Wu YT, Wang SY, Yeh CN, Chen TC, Hwang TL. CD44 Predicts Early Recurrence in Pancreatic Cancer Patients Undergoing Radical Surgery. In Vivo (Athens, Greece). 32: 1533-1540. PMID 30348713 DOI: 10.21873/invivo.11411  0.085
2016 Chen YH, Chung CC, Liu YC, Yeh SP, Hsu JL, Hung MC, Su HL, Li LY. EZH2 and HDAC9c regulate age-dependent mesenchymal stem cell differentiation into osteoblasts and adipocytes. Stem Cells (Dayton, Ohio). PMID 27250566 DOI: 10.1002/Stem.2400  0.085
2016 Chen YH, Chung CC, Liu YC, Yeh SP, Hsu JL, Hung MC, Su HL, Li LY. EZH2 and HDAC9c regulate age-dependent mesenchymal stem cell differentiation into osteoblasts and adipocytes. Stem Cells (Dayton, Ohio). PMID 27250566 DOI: 10.1002/Stem.2400  0.085
2020 Wang K, Zelnick LR, Anderson A, Cohen J, Dobre M, Deo R, Feldman H, Go A, Hsu J, Jaar B, Kansal M, Shlipak M, Soliman E, Rao P, Weir M, et al. Cardiac Biomarkers and Risk of Mortality in CKD (the CRIC Study). Kidney International Reports. 5: 2002-2012. PMID 33163721 DOI: 10.1016/j.ekir.2020.08.028  0.085
2018 Harrison TN, Hsu JY, Rosenson RS, Levitan EB, Muntner P, Cheetham TC, Wei R, Scott RD, Reynolds K. Unmet Patient Need in Statin Intolerance: the Clinical Characteristics and Management. Cardiovascular Drugs and Therapy. PMID 29417422 DOI: 10.1007/S10557-018-6775-0  0.085
2016 DeFilipp Z, Duarte RF, Snowden JA, Majhail NS, Greenfield DM, Miranda JL, Arat M, Baker KS, Burns LJ, Duncan CN, Gilleece M, Hale GA, Hamadani M, Hamilton BK, Hogan WJ, ... Hsu JW, et al. Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT. Bone Marrow Transplantation. PMID 27548466 DOI: 10.1038/bmt.2016.203  0.085
2020 Hsu JY, Major JL, Riching AS, Sen R, Pires da Silva J, Bagchi RA. Beyond the Genome: Challenges and Potential for Epigenetics-driven Therapeutic Approaches in Pulmonary Arterial Hypertension. Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire. PMID 32706995 DOI: 10.1139/bcb-2020-0039  0.085
2019 Matsen FA, Whitson A, Jackins SE, Hsu JE. Significant improvement in patient self-assessed comfort and function at six weeks after the smooth and move procedure for shoulders with irreparable rotator cuff tears and retained active elevation. International Orthopaedics. PMID 30903255 DOI: 10.1007/s00264-019-04310-4  0.085
2021 Lam WY, Tang CS, So MT, Yue H, Hsu JS, Chung PH, Nicholls JM, Yeung F, Lee CD, Ngo DN, Nguyen PAH, Mitchison HM, Jenkins D, O'Callaghan C, Garcia-Barceló MM, et al. Identification of a wide spectrum of ciliary gene mutations in nonsyndromic biliary atresia patients implicates ciliary dysfunction as a novel disease mechanism. Ebiomedicine. 71: 103530. PMID 34455394 DOI: 10.1016/j.ebiom.2021.103530  0.085
2020 Cantu E, Bermudez C, Cevasco M, Suzuki Y, Buckley T, Galati V, Majeti N, Benvenuto L, Anderson M, Wille KM, Weinacker A, Dhillon G, Orens J, Shah P, Lama V, ... ... Hsu J, et al. Implications of ECMO Bridging and Salvage Strategies on Mortality and PGD. The Journal of Heart and Lung Transplantation : the Official Publication of the International Society For Heart Transplantation. 39: S103-S104. PMID 32464790 DOI: 10.1016/J.Healun.2020.01.960  0.085
2018 Williams JS, Hsu JY, Rossi CC, Artinger KB. Requirement of zebrafish pcdh10a and pcdh10b in melanocyte precursor migration. Developmental Biology. PMID 29604249 DOI: 10.1016/J.Ydbio.2018.03.022  0.084
2020 Chang RW, Rothenberg KA, Harris JE, Gologorsky RC, Hsu JH, Rehring TF, Hajarizadeh H, Nelken NA, Paxton EW, Prentice HA. Mid-term outcomes for 605 patients receiving Endologix AFX or AFX2 Endovascular AAA Systems in an integrated healthcare system. Journal of Vascular Surgery. PMID 32623106 DOI: 10.1016/J.Jvs.2020.06.048  0.084
2017 Hsu JT, Chung CM, Chu CM, Lin YS, Pan KL, Chang JJ, Wang PC, Chang ST, Yang TY, Jang SJ, Yang TH, Hsiao JF. Predictors of Left Ventricle Remodeling: Combined Plasma B-type Natriuretic Peptide Decreasing Ratio and Peak Creatine Kinase-MB. International Journal of Medical Sciences. 14: 75-85. PMID 28138312 DOI: 10.7150/ijms.17145  0.084
2020 Holland CT, Hsu J, Walker AM. S179D Prolactin Sensitizes Human PC3 Prostate Cancer Xenografts to Anti-tumor Effects of Well-Tolerated Doses of Calcitriol. Journal of Cancer Science and Clinical Therapeutics. 4: 442-456. PMID 33179012 DOI: 10.26502/jcsct.5079085  0.084
2021 Schiffman CJ, Prabhakar P, Hsu JE, Shaffer ML, Miljacic L, Matsen FA. Assessing the Value to the Patient of New Technologies in Anatomic Total Shoulder Arthroplasty. The Journal of Bone and Joint Surgery. American Volume. PMID 33587515 DOI: 10.2106/JBJS.20.01853  0.084
2018 Hsu JI, Dayaram T, Tovy A, De Braekeleer E, Jeong M, Wang F, Zhang J, Heffernan TP, Gera S, Kovacs JJ, Marszalek JR, Bristow C, Yan Y, Garcia-Manero G, Kantarjian H, et al. PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy. Cell Stem Cell. 23: 700-713.e6. PMID 30388424 DOI: 10.1016/J.Stem.2018.10.004  0.084
2017 Nishimura M, Sab S, Reeves RR, Hsu JC. Percutaneous left atrial appendage occlusion in atrial fibrillation patients with a contraindication to oral anticoagulation: a focused review. Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups On Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology. PMID 29228158 DOI: 10.1093/europace/eux313  0.083
2020 Lin YT, Hsu JW, Huang KL, Tsai SJ, Su TP, Li CT, Lin WC, Chen TJ, Bai YM, Chen MH. Sexually transmitted infections among adolescents with conduct disorder: a nationwide longitudinal study. European Child & Adolescent Psychiatry. PMID 32725481 DOI: 10.1007/s00787-020-01605-5  0.083
2019 Kleinstiver BP, Sousa AA, Walton RT, Tak YE, Hsu JY, Clement K, Welch MM, Horng JE, Malagon-Lopez J, Scarfò I, Maus MV, Pinello L, Aryee MJ, Joung JK. Engineered CRISPR-Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing. Nature Biotechnology. PMID 30742127 DOI: 10.1038/S41587-018-0011-0  0.083
2018 Wang YN, Lee HH, Chou CK, Yang WH, Wei Y, Chen CT, Yao J, Hsu JL, Zhu C, Ying H, Ye Y, Wang WJ, Lim SO, Xia W, Ko HW, et al. Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer. Cancer Cell. PMID 29606349 DOI: 10.1016/J.Ccell.2018.02.012  0.083
2017 Hsu JY, Roy JA, Xie D, Yang W, Shou H, Anderson AH, Landis JR, Jepson C, Wolf M, Isakova T, Rahman M, Feldman HI. Statistical Methods for Cohort Studies of CKD: Survival Analysis in the Setting of Competing Risks. Clinical Journal of the American Society of Nephrology : Cjasn. PMID 28242844 DOI: 10.2215/Cjn.10301016  0.083
2020 Chen IC, Hsu JS, Chen YW, Liu YC, Wu YH, Hsu JH, Cheng YF, Dai ZK. Post-infectious Bronchiolitis Obliterans: HRCT, DECT, Pulmonary Scintigraphy Images, and Clinical Follow-up in Eight Children. Frontiers in Pediatrics. 8: 622065. PMID 33392122 DOI: 10.3389/fped.2020.622065  0.083
2020 Kong D, Zhou H, Neelakantan D, Hughes CJ, Hsu JY, Srinivasan RR, Lewis MT, Ford HL. VEGF-C mediates tumor growth and metastasis through promoting EMT-epithelial breast cancer cell crosstalk. Oncogene. PMID 33299122 DOI: 10.1038/s41388-020-01539-x  0.083
2016 Huang CC, Liao PC, Ke SR, Hsu JC. TCT-21 Door-to-ECMO before Door-to-Balloon? Early Implementation of ECMO might improve the Survival of Patients with STEMI Complicated by Refractory Cardiogenic Shock. Journal of the American College of Cardiology. 68: B9. PMID 27970395 DOI: 10.1016/j.jacc.2016.09.897  0.083
2020 Chan SH, Leu WJ, Swain SP, Hsu JL, Hou DR, Guh JH. Mechanistic Study of Triazole Based Aminodiol Derivatives in Leukemic Cells-Crosstalk between Mitochondrial Stress-Involved Apoptosis and Autophagy. International Journal of Molecular Sciences. 21. PMID 32252439 DOI: 10.3390/ijms21072470  0.083
2016 Sheean AJ, Tennent DJ, Owens JG, Wilken JM, Hsu JR, Stinner DJ. Effect of Custom Orthosis and Rehabilitation Program on Outcomes Following Ankle and Subtalar Fusions. Foot & Ankle International. PMID 27521355 DOI: 10.1177/1071100716660821  0.083
2021 Pasupula DK, Munir MB, Bhat A, Siddappa Malleshappa SK, Meera SJ, Spooner M, Koranne K, Olshansky B, Hirji S, Hsu JC. Outcomes and Predictors of Readmission after Implantation of a Percutaneous Left Atrial Appendage Occlusion device in the United States: A Propensity Score-matched Analysis from the National Readmission Database. Journal of Cardiovascular Electrophysiology. PMID 34535939 DOI: 10.1111/jce.15247  0.083
2021 Chung HY, Hsu CC, Hung YL, Chen HW, Wong MS, Fu CY, Tsai CY, Chen MY, Wang SY, Hsu JT, Yeh TS, Yeh CN, Jan YY. Alternative application of percutaneous cholecystostomy in patients with biliary obstruction. Abdominal Radiology (New York). PMID 33388808 DOI: 10.1007/s00261-020-02898-5  0.083
2019 Chang CH, Chang HL, Hsu JF, Yang CJ. Rifampin may decrease the efficacy of crizotinib in lung cancer treatment. The Kaohsiung Journal of Medical Sciences. PMID 31050169 DOI: 10.1002/kjm2.12078  0.082
2020 Sharifi H, Lai YK, Guo H, Hoppenfeld M, Guenther ZD, Johnston L, Brondstetter T, Chhatwani L, Nicolls MR, Hsu JL. Machine learning algorithms to differentiate among pulmonary complications after hematopoietic cell transplant. Chest. PMID 32343962 DOI: 10.1016/j.chest.2020.02.076  0.082
2020 Hsu JE. CORR Insights®: What Factors are Associated with Revision or Worse Patient-reported Outcomes after Reverse Shoulder Arthroplasty for Cuff-tear Arthropathy? A Study from the Danish Shoulder Arthroplasty Register. Clinical Orthopaedics and Related Research. PMID 32091428 DOI: 10.1097/CORR.0000000000001176  0.082
2019 Hsu J, de la Fuente M, Radermacher K. Corrigendum to "Calculation of impingement-free combined cup and stem alignments based on the patient-specific pelvic tilt" [J. Biomech. 82 (2019) 193-203]. Journal of Biomechanics. PMID 31109726 DOI: 10.1016/j.jbiomech.2019.05.008  0.082
2018 Whelan RL, Shaffer A, Anderson ME, Hsu J, Jabbour N. Reducing rates of operative intervention for pediatric post-tonsillectomy hemorrhage. The Laryngoscope. PMID 29314032 DOI: 10.1002/lary.27076  0.082
2018 Chen TH, Lin WR, Lee C, Chiu CT, Hsu JT, Yeh TS, Lin KH, Le PH, Yeh CT. Prognostic Stratification of Advanced Gastric Signet Ring Cell Carcinoma by Clinicopathological Factors and Genotype. Journal of Cancer. 9: 3540-3547. PMID 30310511 DOI: 10.7150/Jca.26293  0.082
2019 Choe H, Gergis U, Hsu J, Phillips A, Shore T, Christos P, van Besien K, Mayer S. Bortezomib and Immune Globulin Have Limited Effects on Donor-Specific HLA Antibodies in Haploidentical Cord Blood Stem Cell Transplantation: Detrimental Effect of Persistent Haploidentical Donor-Specific HLA Antibodies. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 25: e60-e64. PMID 30661542 DOI: 10.1016/j.bbmt.2018.10.018  0.082
2020 Grams ME, Surapaneni A, Appel LJ, Lash JP, Hsu J, Diamantidis CJ, Rosas SE, Fink JC, Scialla JJ, Sondheimer J, Hsu CY, Cheung AK, Jaar BG, Navaneethan S, Cohen DL, et al. Clinical events and patient-reported outcome measures during CKD progression: findings from the CRIC study. Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association. PMID 33326030 DOI: 10.1093/ndt/gfaa364  0.082
2017 Hsieh MJ, Lin YC, Lai RS, Wu CL, Lai CL, Wang CC, Perng DW, Kao SJ, Chang ET, Wang HC, Perng WC, Hsu JY, Lin CH, Tsai YH. Comparative efficacy and tolerability of beclomethasone/formoterol and fluticasone/salmeterol fixed combination in Taiwanese asthmatic patients. Journal of the Formosan Medical Association = Taiwan Yi Zhi. PMID 29292054 DOI: 10.1016/j.jfma.2017.12.005  0.082
2021 Burns EA, Ensor JE, Hsu J, Thomas JS, Olsen RJ, Bernicker EH. Outcomes and prognostic contributors in patients with mutated non-small cell pulmonary adenocarcinomas: a single institution experience. Journal of Thoracic Disease. 13: 4785-4796. PMID 34527319 DOI: 10.21037/jtd-21-432  0.082
1999 Kuo S, Chesrown SE, Mellott JK, Rogers RJ, Hsu JL, Nick HS. In vivo architecture of the manganese superoxide dismutase promoter. The Journal of Biological Chemistry. 274: 3345-54. PMID 9920876 DOI: 10.1074/Jbc.274.6.3345  0.082
1999 Kuo S, Chesrown SE, Mellott JK, Rogers RJ, Hsu JL, Nick HS. In vivo architecture of the manganese superoxide dismutase promoter. The Journal of Biological Chemistry. 274: 3345-54. PMID 9920876 DOI: 10.1074/Jbc.274.6.3345  0.082
1999 Kuo S, Chesrown SE, Mellott JK, Rogers RJ, Hsu JL, Nick HS. In vivo architecture of the manganese superoxide dismutase promoter. The Journal of Biological Chemistry. 274: 3345-54. PMID 9920876 DOI: 10.1074/Jbc.274.6.3345  0.082
1999 Kuo S, Chesrown SE, Mellott JK, Rogers RJ, Hsu JL, Nick HS. In vivo architecture of the manganese superoxide dismutase promoter. The Journal of Biological Chemistry. 274: 3345-54. PMID 9920876 DOI: 10.1074/Jbc.274.6.3345  0.082
2018 Yen HC, Lin CL, Chen BS, Chen CW, Wei KC, Yang ML, Hsu JC, Hsu YH. Alterations of the levels of primary antioxidant enzymes in different grades of human astrocytoma tissues. Free Radical Research. 1-281. PMID 29862858 DOI: 10.1080/10715762.2018.1483580  0.082
2016 Liu CW, Liao PC, Chen KC, Hsu JC, Li AH, Tu CM, Wu YW. Baseline Hemoglobin Levels Associated with One-Year Mortality in ST-Segment Elevation Myocardial Infarction Patients. Acta Cardiologica Sinica. 32: 656-666. PMID 27899852  0.082
2017 Zhen T, Kwon E, Zhao L, Hsu J, Hyde RK, Lu Y, Alemu L, Speck NA, Liu PP. CHD7 deficiency delays leukemogenesis in mice induced by CBFB-MYH11. Blood. PMID 29018080 DOI: 10.1182/Blood-2017-04-780106  0.081
2021 Hsu JW, Farhadfar N, Murthy H, Logan BR, Bo-Subait S, Frey N, Goldstein SC, Horowitz MM, Lazarus H, Schwanke JD, Shah NN, Spellman SR, Switzer GE, Devine SM, Shaw BE, et al. The Effect of Donor Graft Cryopreservation on Allogeneic Hematopoietic Cell Transplantation Outcomes: A Center for International Blood and Marrow Transplant Research Analysis. Implications during the COVID-19 Pandemic. Transplantation and Cellular Therapy. PMID 33865804 DOI: 10.1016/j.jtct.2021.03.015  0.081
2017 Pang SY, Teo KC, Hsu JS, Chang RS, Li M, Sham PC, Ho SL. The role of gene variants in the pathogenesis of neurodegenerative disorders as revealed by next generation sequencing studies: a review. Translational Neurodegeneration. 6: 27. PMID 29046784 DOI: 10.1186/s40035-017-0098-0  0.081
2018 Kuo YC, Au HK, Hsu JL, Wang HF, Lee CJ, Peng SW, Lai SC, Wu YC, Ho HN, Huang YH. IGF-1R Promotes Symmetric Self-Renewal and Migration of Alkaline Phosphatase+ Germ Stem Cells through HIF-2α-OCT4/CXCR4 Loop under Hypoxia. Stem Cell Reports. PMID 29307582 DOI: 10.1016/j.stemcr.2017.12.003  0.081
2017 García-Albéniz X, Hsu J, Hernán MA. The value of explicitly emulating a target trial when using real world evidence: an application to colorectal cancer screening. European Journal of Epidemiology. PMID 28748498 DOI: 10.1007/s10654-017-0287-2  0.081
2017 Hsu JY, Chang JY, Chang KY, Chang WC, Chen BK. Epidermal growth factor-induced pyruvate dehydrogenase kinase 1 expression enhances head and neck squamous cell carcinoma metastasis via up-regulation of fibronectin. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. PMID 28596235 DOI: 10.1096/fj.201700156R  0.081
2017 Diane Mok TY, Tseng MH, Chiang MC, Lin JL, Chu SM, Hsu JF, Lien R. Renal replacement therapy in the neonatal intensive care unit. Pediatrics and Neonatology. PMID 29396136 DOI: 10.1016/j.pedneo.2017.11.015  0.081
2018 Calkins H, Gliklich RE, Leavy MB, Piccini JP, Hsu JC, Mohanty S, Lewis W, Nazarian S, Turakhia MP. Harmonized Outcome Measures for Use in Atrial Fibrillation Patient Registries and Clinical Practice: Endorsed by the Heart Rhythm Society Board of Trustees. Heart Rhythm. PMID 30449519 DOI: 10.1016/J.Hrthm.2018.09.021  0.081
2017 Wu IH, Tsai MH, Lai MY, Hsu LF, Chiang MC, Lien R, Fu RH, Huang HR, Chu SM, Hsu JF. Incidence, clinical features, and implications on outcomes of neonatal late-onset sepsis with concurrent infectious focus. Bmc Infectious Diseases. 17: 465. PMID 28673280 DOI: 10.1186/s12879-017-2574-7  0.081
2021 Lai YJ, Chao CH, Liao CC, Lee TA, Hsu JM, Chou WC, Wang J, Huang HC, Chang SJ, Lin YL, Li CW. Epithelial-mesenchymal transition induced by SARS-CoV-2 required transcriptional upregulation of Snail. American Journal of Cancer Research. 11: 2278-2290. PMID 34094684  0.081
2021 Kou HW, Yeh CN, Tsai CY, Hsu JT, Wang SY, Lee CW, Yu MC, Hwang TL. Clinical benefits of routine examination and synchronous repair of occult inguinal hernia during laparoscopic peritoneal dialysis catheter insertion: a single-center experience. Hernia : the Journal of Hernias and Abdominal Wall Surgery. PMID 33548007 DOI: 10.1007/s10029-020-02364-7  0.081
2013 Yu YL, Chou RH, Shyu WC, Hsieh SC, Wu CS, Chiang SY, Chang WJ, Chen JN, Tseng YJ, Lin YH, Lee W, Yeh SP, Hsu JL, Yang CC, Hung SC, et al. Smurf2-mediated degradation of EZH2 enhances neuron differentiation and improves functional recovery after ischaemic stroke. Embo Molecular Medicine. 5: 531-47. PMID 23526793 DOI: 10.1002/emmm.201201783  0.081
2019 Gomez D, Larsen K, Burns BJ, Dinh M, Hsu J. Optimizing access and configuration of trauma centre care in New South Wales. Injury. PMID 30846283 DOI: 10.1016/j.injury.2019.02.018  0.081
2017 Alvey CM, Spinler KR, Irianto J, Pfeifer CR, Hayes B, Xia Y, Cho S, Dingal PCPD, Hsu J, Smith L, Tewari M, Discher DE. SIRPA-Inhibited, Marrow-Derived Macrophages Engorge, Accumulate, and Differentiate in Antibody-Targeted Regression of Solid Tumors. Current Biology : Cb. PMID 28669759 DOI: 10.1016/J.Cub.2017.06.005  0.081
2019 Lee ML, Sulistyowati E, Hsu JH, Huang BY, Dai ZK, Wu BN, Chao YY, Yeh JL. KMUP-1 Ameliorates Ischemia-Induced Cardiomyocyte Apoptosis through the NO⁻cGMP⁻MAPK Signaling Pathways. Molecules (Basel, Switzerland). 24. PMID 30965668 DOI: 10.3390/molecules24071376  0.08
2016 Arbit B, Nishimura M, Hsu JC. Reversal agents for direct oral anticoagulants: A focused review. International Journal of Cardiology. 223: 244-250. PMID 27541665 DOI: 10.1016/j.ijcard.2016.07.304  0.08
2017 Kao WH, Hong JH, See LC, Yu HP, Hsu JT, Chou IJ, Chou WC, Chiou MJ, Wang CC, Kuo CF. Validity of cancer diagnosis in the National Health Insurance database compared with the linked National Cancer Registry in Taiwan. Pharmacoepidemiology and Drug Safety. PMID 28815803 DOI: 10.1002/pds.4267  0.08
2017 Toda T, Hsu JY, Linker SB, Hu L, Schafer ST, Mertens J, Jacinto FV, Hetzer MW, Gage FH. Nup153 Interacts with Sox2 to Enable Bimodal Gene Regulation and Maintenance of Neural Progenitor Cells. Cell Stem Cell. PMID 28919367 DOI: 10.1016/J.Stem.2017.08.012  0.08
2017 Somerson JS, Neradilek MB, Service BC, Hsu JE, Russ SM, Matsen FA. Clinical and Radiographic Outcomes of the Ream-and-Run Procedure for Primary Glenohumeral Arthritis. The Journal of Bone and Joint Surgery. American Volume. 99: 1291-1304. PMID 28763415 DOI: 10.2106/JBJS.16.01201  0.08
2020 Cheng SL, Ho ML, Lai YF, Wang HC, Hsu JY, Liu SF, Huang MS, Lee CH, Lin CH, Hang LW, Liu YC, Yang KY, Wang JH. Budesonide/Formoterol Anti-Inflammatory Reliever and Maintenance or Fluticasone Propionate/Salmeterol Plus As-Needed, Short-Acting β Agonist: Real-World Effectiveness in pAtients without Optimally Controlled asThma (REACT) Study. Drug Design, Development and Therapy. 14: 5441-5450. PMID 33324041 DOI: 10.2147/DDDT.S266177  0.08
2017 Katz DF, Maddox TM, Turakhia M, Gehi A, O'Brien EC, Lubitz SA, Turchin A, Doros G, Lei L, Varosy P, Marzec L, Hsu JC. Contemporary Trends in Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Low to Moderate Risk of Stroke After Guideline-Recommended Change in Use of the CHADS2 to the CHA2DS2-VASc Score for Thromboembolic Risk Assessment: Analysis From the National Cardiovascular Data Registry's Outpatient Practice Innovation and Clinical Excellence Atrial Fibrillation Registry. Circulation. Cardiovascular Quality and Outcomes. 10. PMID 28506981 DOI: 10.1161/Circoutcomes.116.003476  0.08
2021 Vatansever EC, Yang KS, Drelich AK, Kratch KC, Cho CC, Kempaiah KR, Hsu JC, Mellott DM, Xu S, Tseng CK, Liu WR. Bepridil is potent against SARS-CoV-2 in vitro. Proceedings of the National Academy of Sciences of the United States of America. 118. PMID 33597253 DOI: 10.1073/pnas.2012201118  0.08
2017 Kim J, Sinha S, Solomon M, Perez-Herrero E, Hsu J, Tsinas Z, Muro S. Co-coating of receptor-targeted drug nanocarriers with anti-phagocytic moieties enhances specific tissue uptake versus non-specific phagocytic clearance. Biomaterials. 147: 14-25. PMID 28923682 DOI: 10.1016/j.biomaterials.2017.08.045  0.08
2016 Liu KH, Hung CY, Lu CH, Hsu JT, Yeh TS, Lin YC, Hung YS, Chou WC. Survival outcomes of geriatric patients with clinically resectable gastric cancer: to operate or not. The Journal of Surgical Research. 206: 481-489. PMID 27884346 DOI: 10.1016/j.jss.2016.08.040  0.08
2016 Moura LM, Schwamm EL, Moura Junior V, Seitz MP, Hoch DB, Hsu J, Schwamm LH. Patient-reported financial barriers to adherence to treatment in neurology. Clinicoeconomics and Outcomes Research : Ceor. 8: 685-694. PMID 27895506 DOI: 10.2147/CEOR.S119971  0.08
2017 de la Cruz-Merino L, Di Guardo L, Grob JJ, Venosa A, Larkin J, McArthur GA, Ribas A, Ascierto PA, Evans JTR, Gomez-Escobar A, Barteselli G, Eng S, Hsu JJ, Uyei A, Dréno B. Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study. Journal of Translational Medicine. 15: 146. PMID 28646893 DOI: 10.1186/s12967-017-1246-0  0.08
2016 Chen YJ, Huang CG, Hsu JC, Wu WJ. Development of a Larval Bioassay Method Using 96-Well Microtiter Plates for Evaluation of Susceptibility of the Cat Fleas (Siphonaptera: Pulicidae) to Insecticides. Journal of Medical Entomology. PMID 27614898 DOI: 10.1093/jme/tjw156  0.08
2021 Su IM, Huang HK, Liu PP, Hsu JY, Lin SM, Loh CH. Mortality risk from acute aortic dissection among hospital admissions during weekends and holiday season. Plos One. 16: e0255942. PMID 34469438 DOI: 10.1371/journal.pone.0255942  0.08
2020 Hsu JM, Clark PT, Connell LE, Welfare M. Efficacy of high-flow nasal prong therapy in trauma patients with rib fractures and high-risk features for respiratory deterioration: a randomized controlled trial. Trauma Surgery & Acute Care Open. 5: e000460. PMID 32885050 DOI: 10.1136/tsaco-2020-000460  0.08
2020 Lin CC, Huang YK, Cho CF, Lin YS, Lo CC, Kuo TT, Tseng GC, Cheng WC, Chang WC, Hsiao TH, Lai LC, Shih JY, Liu YH, Chao KSC, Hsu JL, et al. Targeting positive feedback between BASP1 and EGFR as a therapeutic strategy for lung cancer progression. Theranostics. 10: 10925-10939. PMID 33042262 DOI: 10.7150/Thno.49425  0.08
2016 Yang NP, Phan DV, Lee YH, Hsu JC, Pan RH, Chan CL, Chang NT, Chu D. Retrospective one-million-subject fixed-cohort survey of utilization of emergency departments due to traumatic causes in Taiwan, 2001-2010. World Journal of Emergency Surgery : Wjes. 11: 41. PMID 27579054 DOI: 10.1186/s13017-016-0098-x  0.08
2018 Chuang CH, Hsu JF, Shen YT, Yang CJ. Regression of a metastatic lung mass after receiving whole brain irradiation: Can the abscopal effect cross the blood-brain barrier? Asia-Pacific Journal of Clinical Oncology. PMID 29984499 DOI: 10.1111/ajco.13051  0.079
2018 Lubitz SA, Khurshid S, Weng LC, Doros G, Keach JW, Gao Q, Gehi AK, Hsu JC, Reynolds MR, Turakhia MP, Maddox TM. Predictors of oral anticoagulant non-prescription in patients with atrial fibrillation and elevated stroke risk. American Heart Journal. 200: 24-31. PMID 29898845 DOI: 10.1016/J.Ahj.2018.03.003  0.079
2020 Zhou C, Weng J, Liu C, Zhou Q, Chen W, Hsu JL, Sun J, Atyah M, Xu Y, Shi Y, Shen Y, Dong Q, Hung MC, Ren N. High RPS3A expression correlates with low tumor immune cell infiltration and unfavorable prognosis in hepatocellular carcinoma patients. American Journal of Cancer Research. 10: 2768-2784. PMID 33042616  0.079
2021 Rigert JM, Napenas JJ, Wally M, Odum S, Yu Z, Runyon M, Hsu JR, Seymour RB. Dental pain management with prescription opioids by nondental healthcare professionals in a healthcare system network. Journal of Public Health Dentistry. PMID 34080195 DOI: 10.1111/jphd.12459  0.079
2019 Lee D, Hoffmayer KS, Hsu JC, Schricker A, Birgersdotter-Green U, Raissi F, Feld GK, Krummen DE. Long-term mode and timing of premature ventricular complex recurrence following successful catheter ablation. Journal of Interventional Cardiac Electrophysiology : An International Journal of Arrhythmias and Pacing. PMID 30734139 DOI: 10.1007/s10840-019-00520-3  0.079
2017 Hsu JC, Hoffmayer KS. The Relationship of Antitachycardia Pacing versus Shock in an Implantable Cardioverter-Defibrillator Population and the Risk of Mortality: Just an Association? Journal of Cardiovascular Electrophysiology. PMID 28176398 DOI: 10.1111/jce.13172  0.079
2020 Beache GM, Mohammed TH, Hurwitz Koweek LM, Ghoshhajra BB, Brown RKJ, Davis AM, Heitner J, Hsu JY, Johri AM, Khosa F, Kligerman SJ, Litmanovich D, Maroules CD, Meyersohn N, et al. ACR Appropriateness Criteria® Acute Nonspecific Chest Pain-Low Probability of Coronary Artery Disease. Journal of the American College of Radiology : Jacr. 17: S346-S354. PMID 33153548 DOI: 10.1016/j.jacr.2020.09.006  0.079
2016 Hsu J, Sage J. Novel Functions for the Transcription Factor E2F4 in Development and Disease. Cell Cycle (Georgetown, Tex.). 0. PMID 27753528 DOI: 10.1080/15384101.2016.1234551  0.079
2016 Petfield JL, Hayeck GT, Kopperdahl DL, Nesti LJ, Keaveny TM, Hsu JR. Virtual stress testing of fracture stability in soldiers with severely comminuted tibial fractures. Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society. PMID 27302535 DOI: 10.1002/jor.23335  0.079
2021 Gilbert M, Goilav B, Hsu JJ, Nietert PJ, Meidan E, Chua A, Ardoin SP, Wenderfer SE, von Scheven E, Ruth NM. Differences in rituximab use between pediatric rheumatologists and nephrologists for the treatment of refractory lupus nephritis and renal flare in childhood-onset SLE. Pediatric Rheumatology Online Journal. 19: 137. PMID 34461932 DOI: 10.1186/s12969-021-00627-w  0.079
2017 Yang W, Jepson C, Xie D, Roy JA, Shou H, Hsu JY, Anderson AH, Landis JR, He J, Feldman HI. Statistical Methods for Recurrent Event Analysis in Cohort Studies of CKD. Clinical Journal of the American Society of Nephrology : Cjasn. PMID 28716856 DOI: 10.2215/CJN.12841216  0.079
2018 Obeid A, Gao X, Ali FS, Talcott KE, Aderman CM, Hyman L, Ho AC, Hsu J. Loss to Follow-Up in Patients with Proliferative Diabetic Retinopathy after Panretinal Photocoagulation or Intravitreal Anti-VEGF Injections. Ophthalmology. PMID 29606377 DOI: 10.1016/j.ophtha.2018.02.034  0.079
2017 Lin CM, Xu J, Yang WT, Wang C, Li YC, Cheng LC, Zhang L, Hsu JC. Smurf Downregulates Echinoid in the Amnioserosa To Regulate Drosophila Dorsal Closure. Genetics. PMID 28428287 DOI: 10.1534/genetics.116.196527  0.079
2016 Earl-Royal E, Kaufman EJ, Hsu JY, Wiebe DJ, Reilly PM, Holena DN. Age and preexisting conditions as risk factors for severe adverse events and failure to rescue after injury. The Journal of Surgical Research. 205: 368-377. PMID 27664885 DOI: 10.1016/j.jss.2016.06.082  0.079
2017 Tak YE, Kleinstiver BP, Nuñez JK, Hsu JY, Horng JE, Gong J, Weissman JS, Joung JK. Inducible and multiplex gene regulation using CRISPR-Cpf1-based transcription factors. Nature Methods. PMID 29083402 DOI: 10.1038/Nmeth.4483  0.079
2018 Huang WS, Hsu JW, Huang KL, Bai YM, Su TP, Li CT, Lin WC, Chen TJ, Tsai SJ, Liou YJ, Chen MH. Post-traumatic stress disorder and risk of osteoporosis: A nationwide longitudinal study. Stress and Health : Journal of the International Society For the Investigation of Stress. PMID 29656531 DOI: 10.1002/smi.2806  0.079
2019 Van Besien K, Bachier-Rodriguez L, Satlin M, Brown MA, Gergis U, Guarneri D, Hsu J, Phillips AA, Mayer SA, Singh AD, Soave R, Rossi A, Small CB, Walsh TJ, Rennert H, et al. Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk. Leukemia & Lymphoma. 1-4. PMID 30741059 DOI: 10.1080/10428194.2018.1543877  0.079
2020 Hsu JW, Shaw BE, Kim S, Logan BR, Sees JA, Confer DL, Pulsipher MA, Shah N, Switzer GE, Abidi MH, Ahmed IA, Anderlini PN, Bredseon C, Chhabra S, Dandoy CE, et al. Collection of Peripheral Blood Progenitor Cells in One Day is Associated with Decreased Donor Toxicity compared to Two Days in Unrelated Donors. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 32088366 DOI: 10.1016/J.Bbmt.2020.02.011  0.078
2020 Matsen FA, Whitson AJ, Pottinger PS, Neradilek MB, Hsu JE. Cutaneous microbiology of patients having primary shoulder arthroplasty. Journal of Shoulder and Elbow Surgery. PMID 32247723 DOI: 10.1016/j.jse.2019.12.031  0.078
2016 Moura LM, Schwamm E, Moura Junior V, Seitz MP, Hsu J, Cole AJ, Schwamm LH. Feasibility of the collection of patient-reported outcomes in an ambulatory neurology clinic. Neurology. PMID 27815405 DOI: 10.1212/Wnl.0000000000003409  0.078
2017 Chung CM, Lin MS, Hsu JT, Hsiao JF, Chang ST, Pan KL, Lin CL, Lin YS. Effects of statin therapy on cerebrovascular and renal outcomes in patients with predialysis advanced chronic kidney disease and dyslipidemia. Journal of Clinical Lipidology. 11: 422-431.e2. PMID 28502499 DOI: 10.1016/j.jacl.2017.01.001  0.078
2020 Leu WJ, Wang CT, Hsu JL, Chen IS, Chang HS, Guh JH. Ascleposide, a natural cardenolide, induces anticancer signaling in human castration-resistant prostatic cancer through Na /K -ATPase internalization and tubulin acetylation. The Prostate. PMID 31905252 DOI: 10.1002/pros.23944  0.078
2016 Hsu CP, Hsu JT, Liao CH, Kang SC, Lin BC, Hsu YP, Yeh CN, Yeh TS, Hwang TL. Three-year and five-year outcomes of surgical resection for pancreatic ductal adenocarcinoma: Long-term experiences in one medical center. Asian Journal of Surgery. PMID 28010955 DOI: 10.1016/j.asjsur.2016.11.009  0.078
2017 Kim SH, Kandiah N, Hsu JL, Suthisisang C, Udommongkol C, Dash A. Beyond symptomatic effects: Donepezil's potential for neuroprotection and disease modification in Alzheimer's disease. British Journal of Pharmacology. PMID 28901528 DOI: 10.1111/bph.14030  0.078
2018 Gomez D, Sarrami P, Singh H, Balogh ZJ, Dinh M, Hsu J. External benchmarking of trauma services in New South Wales: Risk-adjusted mortality after moderate to severe injury from 2012 to 2016. Injury. PMID 30274757 DOI: 10.1016/j.injury.2018.09.037  0.078
2017 Cocco AM, Messer D, Brown A, Sriram N, Gilchrist J, Al-Mansouri L, Kefford R, Meybodi F, French J, Hsu J, Elder E. Neoadjuvant systemic therapy for breast cancer: the Westmead experience. Anz Journal of Surgery. PMID 28922685 DOI: 10.1111/ans.14158  0.078
2020 Hsu JB, Lee GA, Chang TH, Huang SW, Le NQK, Chen YC, Kuo DP, Li YT, Chen CY. Radiomic Immunophenotyping of GSEA-Assessed Immunophenotypes of Glioblastoma and Its Implications for Prognosis: A Feasibility Study. Cancers. 12. PMID 33086550 DOI: 10.3390/cancers12103039  0.078
2017 Napierala MA, Bellamy JL, Murray CK, Hurley RK, Wenke JC, Hsu JR. Risk of Obtaining Routine Cultures During Presumed Aseptic Orthopaedic Procedures. Journal of Surgical Orthopaedic Advances. 26: 239-245. PMID 29461197 DOI: https://www.jsoaonline.com/archive/2017/obtaining-routine-cultures-aseptic-orthopaedic-procedures/  0.078
2017 Chiang KC, Yeh TS, Huang CC, Chang YC, Juang HH, Cheng CT, Pang JS, Hsu JT, Takano M, Chen TC, Kittaka A, Hsiao M, Yeh CN. MART-10 represses cholangiocarcinoma cell growth and high vitamin D receptor expression indicates better prognosis for cholangiocarcinoma. Scientific Reports. 7: 43773. PMID 28256614 DOI: 10.1038/srep43773  0.078
2019 Mallalieu NL, Wimalasundera S, Hsu JC, Douglass W, Wells C, Penades IC, Cuttica R, Huppertz HI, Joos R, Kimura Y, Milojevic D, Rosenkranz M, Schikler K, Constantin T, Wouters C. Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial. Pediatric Rheumatology Online Journal. 17: 57. PMID 31438986 DOI: 10.1186/S12969-019-0364-Z  0.078
2020 Med SJB, Mwagiru D, Thakur I, Moghadam A, Oh T, Hsu J. Impact of societal restrictions and lockdown on Trauma admissions during the COVID-19 pandemic: A single centre cross-sectional observational study. Anz Journal of Surgery. PMID 32894624 DOI: 10.1111/ans.16307  0.078
2018 Hsu JM, Li CW, Lai YJ, Hung MC. Posttranslational Modifications of PD-L1 and Their Applications in Cancer Therapy. Cancer Research. 78: 6349-6353. PMID 30442814 DOI: 10.1158/0008-5472.CAN-18-1892  0.078
2017 Wang SY, Hsu CH, Liao CH, Fu CY, Ouyang CH, Cheng CT, Hsu JT, Yeh TS, Yeh CN. Surgical outcome evaluation of perforated gastric cancer: from the aspects of both acute care surgery and surgical oncology. Scandinavian Journal of Gastroenterology. 1-6. PMID 28838270 DOI: 10.1080/00365521.2017.1369562  0.078
2021 Huang HK, Peng CC, Lin SM, Munir KM, Chang RH, Wu BB, Liu PP, Hsu JY, Loh CH, Tu YK. Fracture Risks in Patients Treated With Different Oral Anticoagulants: A Systematic Review and Meta-Analysis. Journal of the American Heart Association. e019618. PMID 33759542 DOI: 10.1161/JAHA.120.019618  0.078
2019 Matsen FA, Whitson A, Hsu JE, Stankovic NK, Neradilek MB, Somerson JS. Prearthroplasty glenohumeral pathoanatomy and its relationship to patient's sex, age, diagnosis, and self-assessed shoulder comfort and function. Journal of Shoulder and Elbow Surgery. PMID 31311749 DOI: 10.1016/j.jse.2019.04.043  0.077
2019 Hsu J, Wang CH, Huang SC, Chen YW, Yu S, Hwang JJ, Lin JW, Ma MC, Chen YS. Novel application of amino-acid buffered solution for neuroprotection against ischemia/reperfusion injury. Plos One. 14: e0221039. PMID 31504040 DOI: 10.1371/journal.pone.0221039  0.077
2018 McKay RR, Bossé D, Xie W, Wankowicz SAM, Flaifel A, Brandao R, Lalani AK, Martini DJ, Wei XX, Braun DA, Van Allen EM, Castellano D, de Velasco G, Wells JC, Heng DYC, ... ... Hsu J, et al. The Clinical Activity of PD-1/PD-L1 inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma. Cancer Immunology Research. PMID 29748390 DOI: 10.1158/2326-6066.Cir-17-0475  0.077
2016 Hsu JC, Hsieh CL, Lu CY. Trend and Geographic Analysis of Prevalence of Dengue in Taiwan (2010-2015). International Journal of Infectious Diseases : Ijid : Official Publication of the International Society For Infectious Diseases. PMID 27865829 DOI: 10.1016/j.ijid.2016.11.008  0.077
2016 Wu JR, Yeh JL, Liou SF, Dai ZK, Wu BN, Hsu JH. Gamma-secretase Inhibitor Prevents Proliferation and Migration of Ductus Arteriosus Smooth Muscle Cells through the Notch3-HES1/2/5 Pathway. International Journal of Biological Sciences. 12: 1063-73. PMID 27570480 DOI: 10.7150/ijbs.16430  0.077
2017 Hsu J, Price M, Vogeli C, Brand R, Chernew ME, Chaguturu SK, Weil E, Ferris TG. Bending The Spending Curve By Altering Care Delivery Patterns: The Role Of Care Management Within A Pioneer ACO. Health Affairs (Project Hope). 36: 876-884. PMID 28461355 DOI: 10.1377/Hlthaff.2016.0922  0.077
2017 Weissler JM, Lanni MA, Hsu JY, Tecce MG, Carney MJ, Kelz RR, Fox JP, Fischer JP. Development of a Clinically Actionable Incisional Hernia Risk Model after Colectomy Using the Healthcare Cost and Utilization Project. Journal of the American College of Surgeons. PMID 28445797 DOI: 10.1016/j.jamcollsurg.2017.04.007  0.077
2021 Schiffman CJ, Whitson AJ, Chawla SS, Matsen FA, Hsu JE. Arthroscopic management of glenohumeral arthritis in the young patient does not negatively impact the outcome of subsequent anatomic shoulder arthroplasty. International Orthopaedics. PMID 34255098 DOI: 10.1007/s00264-021-05133-y  0.077
2018 Hsu JC, Tsai HL, Lin YL, Chang RY. Acute pericarditis following treatment of a metastatic liver tumor with radiofrequency ablation: a case report. Bmc Cardiovascular Disorders. 18: 200. PMID 30348082 DOI: 10.1186/s12872-018-0937-7  0.077
2017 Moura LM, Westover MB, Kwasnik D, Cole AJ, Hsu J. Causal inference as an emerging statistical approach in neurology: an example for epilepsy in the elderly. Clinical Epidemiology. 9: 9-18. PMID 28115873 DOI: 10.2147/Clep.S121023  0.077
2016 Hsu JT, Yeh TS, Jan YY. Role of splenectomy in proximal gastric cancer patients undergoing total gastrectomy. Translational Gastroenterology and Hepatology. 1: 84. PMID 28138649 DOI: 10.21037/tgh.2016.11.02  0.077
2018 Li CW, Lim SO, Chung EM, Kim YS, Park AH, Yao J, Cha JH, Xia W, Chan LC, Kim T, Chang SS, Lee HH, Chou CK, Liu YL, Yeh HC, ... ... Hsu JL, ... ... Hsu JM, et al. Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1. Cancer Cell. 33: 187-201.e10. PMID 29438695 DOI: 10.1016/J.Ccell.2018.01.009  0.077
2017 Yang CJ, Hung JY, Tsai MJ, Wu KL, Liu TC, Chou SH, Lee JY, Hsu JS, Huang MS, Chong IW. The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy. Bmc Pharmacology & Toxicology. 18: 21. PMID 28486985 DOI: 10.1186/s40360-017-0130-0  0.076
2021 O'Toole RV, Joshi M, Carlini AR, Murray CK, Allen LE, Huang Y, Scharfstein DO, O'Hara NN, Gary JL, Bosse MJ, Castillo RC, Bishop JA, Weaver MJ, Firoozabadi R, ... Hsu JR, et al. Effect of Intrawound Vancomycin Powder in Operatively Treated High-risk Tibia Fractures: A Randomized Clinical Trial. Jama Surgery. e207259. PMID 33760010 DOI: 10.1001/jamasurg.2020.7259  0.076
2017 Hsu JT, Hsu CS, Le PH, Chen TC, Chou WC, Lin CY, Yeh TS. Immunochemotherapy benefits in gastric cancer patients stratified by programmed death-1 ligand-1. The Journal of Surgical Research. 211: 30-38. PMID 28501128 DOI: 10.1016/j.jss.2016.11.058  0.076
2020 Chen MK, Hsu JL, Hung MC. Nuclear receptor tyrosine kinase transport and functions in cancer. Advances in Cancer Research. 147: 59-107. PMID 32593407 DOI: 10.1016/Bs.Acr.2020.04.010  0.076
2019 Bumgarner RE, Harrison D, Hsu JE. Isolates from Deep Tissue Specimens Retrieved During Revision Shoulder Arthroplasty: Similar colony morphology does not indicate clonality. Journal of Clinical Microbiology. PMID 31645372 DOI: 10.1128/Jcm.00121-19  0.076
Hide low-probability matches.